<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosmed</journal-id>
<journal-title-group>
<journal-title>PLOS Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1549-1277</issn>
<issn pub-type="epub">1549-1676</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pmed.1002579</article-id>
<article-id pub-id-type="publisher-id">PMEDICINE-D-17-03351</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Women's health</subject><subj-group><subject>Maternal health</subject><subj-group><subject>Pregnancy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Women's health</subject><subj-group><subject>Obstetrics and gynecology</subject><subj-group><subject>Pregnancy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Dose prediction methods</subject><subj-group><subject>Population-based pharmacokinetic dosing</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular anatomy</subject><subj-group><subject>Blood vessels</subject><subj-group><subject>Capillaries</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular anatomy</subject><subj-group><subject>Blood vessels</subject><subj-group><subject>Capillaries</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Parasitic diseases</subject><subj-group><subject>Malaria</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Tropical diseases</subject><subj-group><subject>Malaria</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug absorption</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis</article-title>
<alt-title alt-title-type="running-head">WWARN pooled lumefantrine PK analysis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7213-4559</contrib-id>
<name name-style="western">
<surname>Kloprogge</surname>
<given-names>Frank</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3433-6106</contrib-id>
<name name-style="western">
<surname>Workman</surname>
<given-names>Lesley</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Borrmann</surname>
<given-names>Steffen</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tékété</surname>
<given-names>Mamadou</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lefèvre</surname>
<given-names>Gilbert</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hamed</surname>
<given-names>Kamal</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff010"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Piola</surname>
<given-names>Patrice</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ursing</surname>
<given-names>Johan</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff012"><sup>12</sup></xref>
<xref ref-type="aff" rid="aff013"><sup>13</sup></xref>
<xref ref-type="aff" rid="aff014"><sup>14</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kofoed</surname>
<given-names>Poul Erik</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff014"><sup>14</sup></xref>
<xref ref-type="aff" rid="aff015"><sup>15</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mårtensson</surname>
<given-names>Andreas</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff016"><sup>16</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ngasala</surname>
<given-names>Billy</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff017"><sup>17</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Björkman</surname>
<given-names>Anders</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff018"><sup>18</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9122-8294</contrib-id>
<name name-style="western">
<surname>Ashton</surname>
<given-names>Michael</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff019"><sup>19</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Friberg Hietala</surname>
<given-names>Sofia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff019"><sup>19</sup></xref>
<xref ref-type="aff" rid="aff020"><sup>20</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Aweeka</surname>
<given-names>Francesca</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff021"><sup>21</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Parikh</surname>
<given-names>Sunil</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff022"><sup>22</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mwai</surname>
<given-names>Leah</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff023"><sup>23</sup></xref>
<xref ref-type="aff" rid="aff024"><sup>24</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Davis</surname>
<given-names>Timothy M. E.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff025"><sup>25</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Karunajeewa</surname>
<given-names>Harin</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff026"><sup>26</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8276-6784</contrib-id>
<name name-style="western">
<surname>Salman</surname>
<given-names>Sam</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff025"><sup>25</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9030-5382</contrib-id>
<name name-style="western">
<surname>Checchi</surname>
<given-names>Francesco</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff027"><sup>27</sup></xref>
<xref ref-type="aff" rid="aff028"><sup>28</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3000-6185</contrib-id>
<name name-style="western">
<surname>Fogg</surname>
<given-names>Carole</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff027"><sup>27</sup></xref>
<xref ref-type="aff" rid="aff029"><sup>29</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Newton</surname>
<given-names>Paul N.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff030"><sup>30</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mayxay</surname>
<given-names>Mayfong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff030"><sup>30</sup></xref>
<xref ref-type="aff" rid="aff031"><sup>31</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Deloron</surname>
<given-names>Philippe</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff032"><sup>32</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1629-1194</contrib-id>
<name name-style="western">
<surname>Faucher</surname>
<given-names>Jean François</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff033"><sup>33</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7951-0745</contrib-id>
<name name-style="western">
<surname>Nosten</surname>
<given-names>François</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff034"><sup>34</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7620-4822</contrib-id>
<name name-style="western">
<surname>Ashley</surname>
<given-names>Elizabeth A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff035"><sup>35</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1621-3257</contrib-id>
<name name-style="western">
<surname>McGready</surname>
<given-names>Rose</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff034"><sup>34</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>van Vugt</surname>
<given-names>Michele</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff034"><sup>34</sup></xref>
<xref ref-type="aff" rid="aff036"><sup>36</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4201-5473</contrib-id>
<name name-style="western">
<surname>Proux</surname>
<given-names>Stephane</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff034"><sup>34</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2000-2874</contrib-id>
<name name-style="western">
<surname>Price</surname>
<given-names>Ric N.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff037"><sup>37</sup></xref>
<xref ref-type="aff" rid="aff038"><sup>38</sup></xref>
<xref ref-type="aff" rid="aff039"><sup>39</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Karbwang</surname>
<given-names>Juntra</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff040"><sup>40</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ezzet</surname>
<given-names>Farkad</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff010"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bakshi</surname>
<given-names>Rajesh</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Stepniewska</surname>
<given-names>Kasia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff041"><sup>41</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1897-1978</contrib-id>
<name name-style="western">
<surname>White</surname>
<given-names>Nicholas J.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff042"><sup>42</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6008-2963</contrib-id>
<name name-style="western">
<surname>Guerin</surname>
<given-names>Philippe J.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff041"><sup>41</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Barnes</surname>
<given-names>Karen I.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4566-4030</contrib-id>
<name name-style="western">
<surname>Tarning</surname>
<given-names>Joel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff042"><sup>42</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>WorldWide Antimalarial Resistance Network, Bangkok, Thailand</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Institute for Global Health, University College London, London, United Kingdom</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>WorldWide Antimalarial Resistance Network, Cape Town, South Africa</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Kenya Medical Research Institute–Wellcome Trust Research Programme, Kilifi, Kenya</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Institute for Tropical Medicine, Eberhard Karls University of Tübingen, Tübingen, Germany</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Science, Techniques and Technologies of Bamako, Bamako, Mali</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Novartis, Basel, Switzerland</addr-line></aff>
<aff id="aff010"><label>10</label> <addr-line>Novartis Pharmaceuticals, East Hanover, New Jersey, United States of America</addr-line></aff>
<aff id="aff011"><label>11</label> <addr-line>Institut Pasteur du Cambodge, Phnom Penh, Cambodia</addr-line></aff>
<aff id="aff012"><label>12</label> <addr-line>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden</addr-line></aff>
<aff id="aff013"><label>13</label> <addr-line>Department of Infectious Diseases, Danderyds Hospital, Stockholm, Sweden</addr-line></aff>
<aff id="aff014"><label>14</label> <addr-line>Bandim Health Project, Bissau, Guinea-Bissau</addr-line></aff>
<aff id="aff015"><label>15</label> <addr-line>Department of Paediatrics, Kolding Hospital, Kolding, Denmark</addr-line></aff>
<aff id="aff016"><label>16</label> <addr-line>Department of Women’s and Children’s Health, International Maternal and Child Health, Uppsala University, Uppsala, Sweden</addr-line></aff>
<aff id="aff017"><label>17</label> <addr-line>Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania</addr-line></aff>
<aff id="aff018"><label>18</label> <addr-line>Karolinska Institutet, Stockholm, Sweden</addr-line></aff>
<aff id="aff019"><label>19</label> <addr-line>Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden</addr-line></aff>
<aff id="aff020"><label>20</label> <addr-line>Pharmetheus, Uppsala, Sweden</addr-line></aff>
<aff id="aff021"><label>21</label> <addr-line>UCSF School of Pharmacy, San Francisco, California, United States of America</addr-line></aff>
<aff id="aff022"><label>22</label> <addr-line>Yale School of Public Health, New Haven, Connecticut, United States of America</addr-line></aff>
<aff id="aff023"><label>23</label> <addr-line>Institute for Tropical Medicine and Joanna Briggs Institute Affiliate Centre for Evidence Based Health Care Evidence Synthesis and Translation Unit, Afya Research Africa, Nairobi, Kenya</addr-line></aff>
<aff id="aff024"><label>24</label> <addr-line>International Development Research Centre, Ottawa, Ontario, Canada</addr-line></aff>
<aff id="aff025"><label>25</label> <addr-line>Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia</addr-line></aff>
<aff id="aff026"><label>26</label> <addr-line>Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia</addr-line></aff>
<aff id="aff027"><label>27</label> <addr-line>Epicentre, Paris, France</addr-line></aff>
<aff id="aff028"><label>28</label> <addr-line>Department of Infectious Disease Epidemiology, London School of Hygiene &amp; Tropical Medicine, London, United Kingdom</addr-line></aff>
<aff id="aff029"><label>29</label> <addr-line>Faculty of Science, University of Portsmouth, Portsmouth, United Kingdom</addr-line></aff>
<aff id="aff030"><label>30</label> <addr-line>Lao–Oxford–Mahosot Hospital–Wellcome Trust Research Unit, Vientiane, Laos</addr-line></aff>
<aff id="aff031"><label>31</label> <addr-line>Faculty of Postgraduate Studies, University of Health Sciences, Vientiane, Laos</addr-line></aff>
<aff id="aff032"><label>32</label> <addr-line>UMR216 Institut de Recherche pour le Développement, Faculté de Pharmacie, Université Paris Descartes, Paris, France</addr-line></aff>
<aff id="aff033"><label>33</label> <addr-line>Centre Hospitalier Universitaire, UMR Inserm 1094 NET, Limoges, France</addr-line></aff>
<aff id="aff034"><label>34</label> <addr-line>Shoklo Malaria Research Unit, Mae Sot, Thailand</addr-line></aff>
<aff id="aff035"><label>35</label> <addr-line>Myanmar Oxford Clinical Research Unit, Yangon, Myanmar</addr-line></aff>
<aff id="aff036"><label>36</label> <addr-line>Amsterdam Medical Centre, Amsterdam, The Netherlands</addr-line></aff>
<aff id="aff037"><label>37</label> <addr-line>WorldWide Antimalarial Resistance Network, Darwin, Northern Territory, Australia</addr-line></aff>
<aff id="aff038"><label>38</label> <addr-line>Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia</addr-line></aff>
<aff id="aff039"><label>39</label> <addr-line>Charles Darwin University, Darwin, Northern Territory, Australia</addr-line></aff>
<aff id="aff040"><label>40</label> <addr-line>Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan</addr-line></aff>
<aff id="aff041"><label>41</label> <addr-line>WorldWide Antimalarial Resistance Network, Oxford, United Kingdom</addr-line></aff>
<aff id="aff042"><label>42</label> <addr-line>Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Beeson</surname>
<given-names>James G.</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Burnet Institute, AUSTRALIA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>I have read the journal's policy and the authors of this manuscript have the following competing interests: KIB and NJW are members of the WHO Technical Expert Group (TEG) on Malaria Chemotherapy. KIB is also a member of the WHO TEG on Drug Resistance and Containment. KIB, NJW, JT and SP are members of the WHO Malaria Chemotherapy sub-group on dosage recommendations. GL, KH, FE and RB are employees of Novartis, the manufacturer of the drug that is the subject of this publication. EAA and NJW are members of the Editorial Board of PLOS Medicine. None of the authors declare any other conflict of interest.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">joel@tropmedres.ac</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2018</year>
</pub-date>
<volume>15</volume>
<issue>6</issue>
<elocation-id>e1002579</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Kloprogge et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pmed.1002579"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated <italic>Plasmodium falciparum</italic> malaria. Relatively lower cure rates and lumefantrine levels have been reported in young children and in pregnant women during their second and third trimester. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations.</p>
</sec>
<sec id="sec002">
<title>Methods and findings</title>
<p>A search in PubMed, Embase, ClinicalTrials.gov, Google Scholar, conference proceedings, and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology database identified 31 relevant clinical studies published between 1 January 1990 and 31 December 2012, with 4,546 patients in whom lumefantrine concentrations were measured. Under the auspices of WWARN, relevant individual concentration-time data, clinical covariates, and outcome data from 4,122 patients were made available and pooled for the meta-analysis. The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations. Venous plasma lumefantrine concentrations 7 days after starting standard AL treatment were 24.2% and 13.4% lower in children weighing &lt;15 kg and 15–25 kg, respectively, and 20.2% lower in pregnant women compared with non-pregnant adults. Lumefantrine exposure decreased with increasing pre-treatment parasitaemia, and the dose limitation on absorption of lumefantrine was substantial. Simulations using the lumefantrine pharmacokinetic model suggest that, in young children and pregnant women beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more efficacious than using higher individual doses in the current standard treatment regimen (twice daily for 3 days). The model was developed using venous plasma data from patients receiving intact tablets with fat, and evaluations of alternative dosing regimens were consequently only representative for venous plasma after administration of intact tablets with fat. The absence of artemether-dihydroartemisinin data limited the prediction of parasite killing rates and recrudescent infections. Thus, the suggested optimised dosing schedule was based on the pharmacokinetic endpoint of lumefantrine plasma exposure at day 7.</p>
</sec>
<sec id="sec003">
<title>Conclusions</title>
<p>Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules. These dosing regimens should be evaluated in prospective clinical studies to determine whether they would improve cure rates, demonstrate adequate safety, and thereby prolong the useful therapeutic life of this valuable antimalarial treatment.</p>
</sec>
</abstract>
<abstract abstract-type="toc">
<p>Joel Tarning and colleagues investigate the pharmacokinetic and pharmacodynamic properties of artemether-lumefantrine and its principal metabolite in order to inform optimal dosing regimens for treating malaria in all patients, particularly children and pregnant women.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<sec id="sec004">
<title>Why was this study done?</title>
<list list-type="bullet">
<list-item><p>Artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated <italic>Plasmodium falciparum</italic> malaria, and lower cure rates and lumefantrine exposures have been reported in children below 5 years of age and pregnant women.</p></list-item>
<list-item><p>Pharmacokinetic-pharmacodynamic trials are generally small, and differences in study designs limit the generalisability of the findings.</p></list-item>
<list-item><p>It is crucial to develop an optimised dose regimen that achieves equivalent drug exposure in all patient groups.</p></list-item>
</list>
</sec>
<sec id="sec005">
<title>What did the researchers do and find?</title>
<list list-type="bullet">
<list-item><p>Lumefantrine concentration-time data from 4,122 patients from 26 studies were collated and pooled for an individual participant data meta-analysis.</p></list-item>
<list-item><p>A population pharmacokinetic-pharmacodynamic model was developed for lumefantrine to understand how body weight, pregnancy, and baseline parasite density influence drug levels.</p></list-item>
<list-item><p>Small children and women during their second and third pregnancy trimester displayed lower lumefantrine exposures than non-pregnant adults when receiving the recommended 3-day dosing regimen.</p></list-item>
<list-item><p>The developed lumefantrine population pharmacokinetic model was used to evaluate 3 alternative dosing regimens.</p></list-item>
<list-item><p>A 5-day regimen of current weight-based standard twice-daily doses for small children and pregnant women beyond their first trimester is most favourable from a pharmacological perspective.</p></list-item>
</list>
</sec>
<sec id="sec006">
<title>What do these findings mean?</title>
<list list-type="bullet">
<list-item><p>The proposed AL dosing regimen is expected to provide equivalent lumefantrine exposures safely in all patients as well as to expose one additional asexual life cycle to artemether-dihydroartemisinin.</p></list-item>
<list-item><p>The proposed dosing regimen should not only increase cure rates and slow resistance development but also prolong the useful therapeutic life of AL.</p></list-item>
</list>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004440</institution-id>
<institution>Wellcome Trust</institution>
</institution-wrap>
</funding-source>
<award-id>106698/Z/14/Z</award-id>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000865</institution-id>
<institution>Bill and Melinda Gates Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>OPP1181807</award-id>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Bill and Melinda Gates Foundation</institution>
</funding-source>
<award-id>OPP1099191</award-id>
</award-group>
<funding-statement>The Mahidol-Oxford Tropical Medicine Research Unit is partly funded by the Wellcome Trust of Great Britan (106698/Z/14/Z). The WorldWide Antimalarial Resistance Network is funded by a Bill &amp; Melinda Gates Foundation grant (OPP1181807 started October 2017 and OPP1099191 ended in Sept 2017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="4"/>
<page-count count="27"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Data are available from the WWARN data repository (<ext-link ext-link-type="uri" xlink:href="http://www.wwarn.org/accessing-data" xlink:type="simple">http://www.wwarn.org/accessing-data</ext-link>) for researchers who meet the criteria for access to confidential data.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec007" sec-type="intro">
<title>Introduction</title>
<p>Malaria is a major infectious disease in tropical countries, with an estimated 212 (range 148–304) million infections and 429,000 (range 235,000–639,000) deaths in 2015 [<xref ref-type="bibr" rid="pmed.1002579.ref001">1</xref>]. Over 90% of the global malaria mortality is reported in sub-Saharan Africa. Children under 5 years of age are the most vulnerable, accounting for 70% of all malaria-related deaths [<xref ref-type="bibr" rid="pmed.1002579.ref001">1</xref>]. The World Health Organization recommends that uncomplicated <italic>Plasmodium falciparum</italic> malaria should be treated with an artemisinin-based combination therapy (ACT) [<xref ref-type="bibr" rid="pmed.1002579.ref002">2</xref>]. Artemether-lumefantrine (AL) is the most widely used ACT, accounting for 73% of global ACT procurement in 2013 [<xref ref-type="bibr" rid="pmed.1002579.ref003">3</xref>], which makes it one of the most widely used anti-infective agents in the world today. Furthermore, AL is well tolerated and safe for the treatment of uncomplicated <italic>P</italic>. <italic>falciparum</italic> (and other malaria species) infections in all age groups. This includes young children and pregnant women in their second and third trimesters, groups with increased morbidity and mortality from falciparum malaria [<xref ref-type="bibr" rid="pmed.1002579.ref002">2</xref>]. Sub-optimal drug exposures have been reported following currently recommended doses of AL both in young children and pregnant women in their second and third trimesters [<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref012">12</xref>]. On the other hand, similar exposure in pregnant women during their second and third trimester compared to non-pregnant women has also been observed, although the non-pregnant women in this study might not have been as symptomatic as the pregnant women [<xref ref-type="bibr" rid="pmed.1002579.ref013">13</xref>]. Moreover, the numbers of patients recruited to these clinical trials were generally small, and differences in study design including selection of comparator therapies and dose regimens and co-administration with fat [<xref ref-type="bibr" rid="pmed.1002579.ref014">14</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref015">15</xref>] all limit the generalisability of the findings. A meta-analysis could potentially overcome this by pooling individual patient level data from several different studies and characterising both pharmacological properties and the influence of differences in study design, study size, comparator therapies, dose regimens, and inconsistent co-administration with fat. Lumefantrine exposure at day 7 has been evaluated in a meta-analysis previously, but not using a dynamic modelling approach to characterise and quantify pharmacological properties, the influence of covariates, and the relationship between drug concentrations and study outcome [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>].</p>
<p>The aim of this study was to assemble a large and therefore sufficiently powered pooled dataset of patients to examine the pharmacokinetic properties of lumefantrine. This approach enabled critical re-evaluation of the current twice-daily 3-day dosing regimen of AL, particularly in children and in pregnant women in their second and third trimesters. As both lumefantrine and its principal metabolite, desbutyl-lumefantrine, have antimalarial activity, we also designed a pharmacokinetic analysis incorporating both compounds.</p>
</sec>
<sec id="sec008" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec009">
<title>Model building</title>
<p>Pharmacokinetic data, clinical covariates, and efficacy data from patients treated with AL were used for this individual patient data meta-analysis. A search was conducted in PubMed, Embase, ClinicalTrials.gov, Google Scholar, conference proceedings, and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology publication database to identify relevant antimalarial clinical studies published between 1 January 1990 and 31 December 2012 [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>] in which pharmacokinetic parameters as well as clinical covariates in patients treated with AL were recorded. The search strategy used key terms “lumefantrine pharmacokinetics” or “lumefantrine concentration” and “clinical study”.</p>
<p>Under the auspices of WWARN, investigators were invited to participate in this individual patient data meta-analysis. Individual study protocols were available for all trials included, either from the publication or as a metafile submitted with the raw data. Individual patient data from eligible studies were shared, standardised, and collated using a methodology described in the WWARN clinical and pharmacology data management and statistical analysis plans [<xref ref-type="bibr" rid="pmed.1002579.ref017">17</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref018">18</xref>] and previously published research [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>].</p>
<p>Concentration-time data and clinical covariates from patients contributing 2 or more venous plasma samples were used to build the pharmacokinetic models. Patients contributing only 1 pharmacokinetic sample could not be used for model development as between-patient variability could not be dissected from residual variability. Lumefantrine concentration data in different sampling matrices (i.e., venous blood and capillary plasma and blood) and lumefantrine concentration data after administration of different formulations (i.e., crushed tablets and dispersible tablets) were not used for the formal pharmacokinetic model development due to the sparse sampling schedules (i.e., &lt;2 samples per patient for crushed tablets, dispersible tablets, venous blood, and capillary blood) and to avoid introducing additional sources of variability (i.e., capillary plasma samples). Consequently, lumefantrine concentration-time data in venous blood, capillary blood, and capillary plasma as well as lumefantrine concentration-time data from dispersible tablets and crushed tablets were evaluated using a post hoc correction factor at residual variability level with all other pharmacokinetic parameters fixed. Patients contributing &lt;2 venous plasma samples were used for external validation of the developed population pharmacokinetic models.</p>
<p>Both a lumefantrine population pharmacokinetic model and a separate lumefantrine/desbutyl-lumefantrine population pharmacokinetic drug-metabolite model were developed. The natural logarithms of the concentration data were modelled in NONMEM v.7.3 (ICON Development Solutions, Ellicott City, MD) on a Windows XP operating system (Microsoft, Seattle, WA) with a G95 Fortran compiler (Free Software Foundation, Boston, MA).</p>
<p>The developed lumefantrine population pharmacokinetic model was used to generate individual post hoc pharmacokinetic parameter estimates. The resulting lumefantrine concentration-time profiles were subsequently used to link lumefantrine plasma concentrations and clinical study outcome (i.e., cure defined as absence of PCR-corrected recrudescent infection during follow-up) using a time-to-event approach (pharmacokinetic-pharmacodynamic time-to-event model). All outcome data later than day 42 were censored at day 42, and novel infections were censored. The lumefantrine/desbutyl-lumefantrine drug-metabolite model was not combined with the time-to-event approach due to the small sample size relative to the lumefantrine population pharmacokinetic model.</p>
<p>More technical information regarding the pharmacokinetic model building process and the pharmacokinetic-pharmacodynamic time-to-event model building process can be found in <xref ref-type="supplementary-material" rid="pmed.1002579.s009">S1 Text</xref>.</p>
</sec>
<sec id="sec010">
<title>Dose optimisation simulations</title>
<p>The developed lumefantrine pharmacokinetic model was subsequently used for in silico evaluation and comparison of 3 alternative dosing regimens, with plasma lumefantrine concentration on day 7 selected as the pharmacokinetic endpoint [<xref ref-type="bibr" rid="pmed.1002579.ref019">19</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref020">20</xref>]. This pharmacokinetic endpoint has been used as a target for AL treatment as it correlates with cure rate. The day 7 concentration reflects lumefantrine exposure over the previous 3 asexual cycles (i.e., 6 days for <italic>P</italic>. <italic>falciparum</italic>) [<xref ref-type="bibr" rid="pmed.1002579.ref019">19</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref020">20</xref>]. Plasma or whole blood [<xref ref-type="bibr" rid="pmed.1002579.ref021">21</xref>] lumefantrine concentration on day 7 therefore constitutes a clinically relevant and practical surrogate of overall drug exposure, with suggested target day 7 lumefantrine concentrations of 175 ng/ml, 200 ng/ml, and 280 ng/ml in different studies [<xref ref-type="bibr" rid="pmed.1002579.ref012">12</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref022">22</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref023">23</xref>].</p>
<p>A variety of alternative dosing regimens for young children and pregnant women were simulated, and lumefantrine pharmacokinetic parameters were compared to those following administration of the standard dose regimen in non-pregnant adults. Alternative dosing regimens included an increased dosage (1 extra tablet containing 20 mg artemether and 120 mg lumefantrine added to current weight-based standard dose at each twice-daily dose for 3 days), an extended treatment (5-day regimen of current weight-based standard twice-daily doses), and an intensified treatment (current weight-based standard dosage administered 3 times daily for 3 days). More technical information regarding the in silico dose optimisation simulations can be found in <xref ref-type="supplementary-material" rid="pmed.1002579.s009">S1 Text</xref>.</p>
</sec>
<sec id="sec011">
<title>Ethical approval</title>
<p>All data included in this analysis were obtained in accordance with the laws and ethical approvals applicable in the countries in which the studies were conducted, and were from clinical studies in which blood samples were obtained with the knowledge and consent of the individuals to which they relate. Data were fully anonymised either before or during the process of uploading to the WWARN pharmacology database. Ethical approval to conduct individual participant data pooled analyses was granted to WWARN by the Oxford Tropical Research Ethics Committee (OxTREC).</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<p>Lumefantrine concentration-time data from 4,122 patients from 26 studies were uploaded to the WWARN pharmacology database (<xref ref-type="fig" rid="pmed.1002579.g001">Fig 1</xref>; <xref ref-type="supplementary-material" rid="pmed.1002579.s007">S1 Table</xref>). These data were categorised into 3 different geographic areas (Africa, Oceania, and Southeast Asia) comprising 12 countries (Benin, Guinea-Bissau, Tanzania, Uganda, Kenya, Mali, Mozambique, Liberia, Papua New Guinea, Lao People’s Democratic Republic [Laos], Thailand, and Cambodia). Lumefantrine concentrations were available for analysis in 4 different matrices: 2,312 patients contributed venous plasma samples, 595 patients contributed venous whole blood samples, 191 patients contributed capillary plasma samples, and 840 patients contributed capillary whole blood samples. In total, 154 patients were excluded from the analysis, 71 because of missing dosing information and 83 who took repeated dosing (i.e., retreatment). A further 30 patients were excluded from the evaluation of pre-treatment parasitaemia as a covariate because relevant parasitological data were missing. Venous plasma data from 1,347 out of 2,312 patients who contributed at least 2 samples was used for the development of the lumefantrine population pharmacokinetic model. The remaining 400, 278, and 287 patients contributed only 1 venous plasma sample per patient after treatment with intact, crushed, and dispersible tables, respectively, and were therefore only used for external validation and evaluation of formulation effects in a separate analysis (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>). Approximately 37% of the patients were children below 10 years of age and 3.12% were pregnant women (median [range: interquartile range] 23.0 [13.1–38.0: 19.1–30.0] weeks gestational age). Data from 3,486 patients were available for the development of the pharmacokinetic-pharmacodynamic time-to-event model. Approximately 59% of the patients were below 10 years of age and 4.7% were pregnant women (median [range: interquartile range] 22.0 [13.1–39.0: 18.5–28.0] weeks gestational age). Venous plasma data from 159 patients were used for the development of the simultaneous lumefantrine/desbutyl-lumefantrine population pharmacokinetic model. Approximately 57% of the patients were below 10 years of age and 8.81% were pregnant women (median [range: interquartile range] 23.4 [16.2–38.0: 20.8–30.4] weeks gestational age).</p>
<fig id="pmed.1002579.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Patient data disposition.</title>
<p>PK, pharmacokinetic; WWARN, WorldWide antimalarial resistance Network.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pmed.1002579.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.t001</object-id>
<label>Table 1</label> <caption><title>Demographic summary of the data used for the pharmacokinetic and pharmacokinetic-pharmacodynamic models.</title></caption>
<alternatives>
<graphic id="pmed.1002579.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Model</th>
<th align="left">Data</th>
<th align="left">Studies</th>
<th align="left">Study sites</th>
<th align="left">Study size</th>
<th align="left">Dose regimen</th>
<th align="left">Dose (mg/kg)</th>
<th align="left">Sampling matrix</th>
<th align="left">Sample size LF (&gt;LLOQ)</th>
<th align="left">Samples/patient LF</th>
<th align="left">Sample size DLF (&gt;LLOQ)</th>
<th align="left">Samples/patient DLF</th>
<th align="left">Male/female (%)</th>
<th align="left">Age (years)</th>
<th align="left">Body weight (kg)</th>
<th align="left"><italic>z</italic>-Score (weight for age)</th>
<th align="left">Admission parasitaemia (μl<sup>−1</sup>)</th>
<th align="left">Pregnant women (%)</th>
<th align="left">Estimated gestational age (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="7"><bold>PK LF model data</bold></td>
<td align="left">Model building data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref009">9</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref014">14</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref022">22</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref024">24</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref032">32</xref>]</td>
<td align="left">3, 4, 8, 9, 10, 12, 17, 19</td>
<td align="char" char=".">1,347</td>
<td align="left">6 over 3 days, 6 over 5 days, 4 over 3 days, 3 over 3 days</td>
<td align="left">10.2 [3.2–20.9: 8.9–12.0]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">5,949</td>
<td align="left">3 [2–26: 2–5]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">55.9/44.1</td>
<td align="left">16.6 [0.5–78.0: 6.1–26.9]</td>
<td align="left">42 [6–150: 17–52]</td>
<td align="left">−1.2 [−5.3 to 2.6: −2.0 to −0.5]</td>
<td align="left">9,450 [13–450,000: 2,240–38,700]</td>
<td align="char" char=".">3.1</td>
<td align="left">23 [13–38: 19–30]</td>
</tr>
<tr>
<td align="left">Intact tablets validation data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref027">27</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref028">28</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref030">30</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref032">32</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref036">36</xref>]</td>
<td align="left">7, 9, 12, 15, 17, 20, 19</td>
<td align="char" char=".">400</td>
<td align="left">6 over 3 days, 6 over 5 days, 4 over 3 days, 3 over 3 days</td>
<td align="left">10.0 [6.3–18.8: 8.9–12.0]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">394</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">65.5/34.5</td>
<td align="left">8.0 [0.5–80: 3.0–23.0]</td>
<td align="left">21 [6–72: 12–50]</td>
<td align="left">−1.3 [−5.0 to 3.5: −2.0 to −0.7]</td>
<td align="left">27,300 [21–422,000: 7,540–62,000]</td>
<td align="char" char=".">0.3</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">Crushed tablets data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref037">37</xref>]</td>
<td align="left">1, 5, 11, 13, 21</td>
<td align="char" char=".">278</td>
<td align="left">6 over 3 days</td>
<td align="left">12.0 [8.2–20.0: 10.0–13.8]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">264</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">51.8/48.2</td>
<td align="left">3.4 [0.3–12.4: 2.3–5.6]</td>
<td align="left">13 [6–34: 11–17]</td>
<td align="left">−0.9 [−4.2 to 2.7: −1.6 to −0.4]</td>
<td align="left">30,600 [2,040–629,000: 9,130–72,200]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">Dispersible tablets data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref037">37</xref>]</td>
<td align="left">5, 11, 13, 1, 21</td>
<td align="char" char=".">287</td>
<td align="left">6 over 3 days</td>
<td align="left">12.0 [8.2–21.8: 10.0–14.1]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">275</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">49.8/50.2</td>
<td align="left">3.5 [0.0–12.4: 2.2–5.5]</td>
<td align="left">14 [6–34: 11–17]</td>
<td align="left">−1.0 [−3.8 to 10.5: −1.7 to −0.1]</td>
<td align="left">25,000 [520–197,000: 11,500–60,100]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">Venous blood data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref038">38</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref039">39</xref>]</td>
<td align="left">14</td>
<td align="char" char=".">595</td>
<td align="left">6 over 3 days</td>
<td align="left">10.9 [5.9–18.9: 9.4–12.6]</td>
<td align="left">Venous blood</td>
<td align="char" char=".">540</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">50.9/49.1</td>
<td align="left">11.0 [1.0–86.7: 6.6–16.2]</td>
<td align="left">28 [7–82: 19–47]</td>
<td align="left">−1.1 [−3.2 to 5.7: −1.7 to −0.3]</td>
<td align="left">976 [16–285,000: 168–7,380]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">Capillary plasma data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref006">6</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref029">29</xref>]</td>
<td align="left">12, 17</td>
<td align="char" char=".">191</td>
<td align="left">6 over 3 days</td>
<td align="left">9.2 [5.8–13.7: 8.1–10.0]</td>
<td align="left">Capillary plasma</td>
<td align="char" char=".">895</td>
<td align="left">5 [1–7: 4–5]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">0/100</td>
<td align="left">23.0 [15.0–42.0: 19.0–27.5]</td>
<td align="left">52 [35–83: 48–59]</td>
<td align="left">—</td>
<td align="left">3,180 [24–194,000: 551–16,000]</td>
<td align="char" char=".">100</td>
<td align="left">23 [13–39: 19–29]</td>
</tr>
<tr>
<td align="left">Capillary blood data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref040">40</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref043">43</xref>]</td>
<td align="left">2, 3, 6, 16, 18, 22</td>
<td align="char" char=".">840</td>
<td align="left">6 over 3 days</td>
<td align="left">12.0 [8.1–24.0: 10.0–14.1]</td>
<td align="left">Capillary blood</td>
<td align="char" char=".">776</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">49.8/50.2</td>
<td align="left">3.0 [0.3–14.6: 1.9–4.3]</td>
<td align="left">12 [5–51: 10–15]</td>
<td align="left">−0.9 [−5.3 to 4.5: −1.7 to −0.1]</td>
<td align="left">35,600 [140–524,000: 9,330–74,400]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left" rowspan="2"><bold>PK LF/DLF model data</bold></td>
<td align="left">Model building data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref009">9</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref026">26</xref>]</td>
<td align="left">8, 10, 17</td>
<td align="char" char=".">159</td>
<td align="left">6 over 3 days</td>
<td align="left">11.2 [3.2–18.5: 9.9–12.9]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">832</td>
<td align="left">4 [2–16: 3–4]</td>
<td align="left">735</td>
<td align="left">3 [2–16: 3–3]</td>
<td align="left">41.5/58.5</td>
<td align="left">10.0 [1.0–78.0: 4.6–17.5]</td>
<td align="left">21 [7–150: 14–44]</td>
<td align="left">−1.7 [−4.1 to 1.1: −2.1 to −1.1]</td>
<td align="left">12,600 [91–4 × 10<sup>5</sup>: 2,240–51,800]</td>
<td align="char" char=".">8.8</td>
<td align="left">23 [16–38: 21–30]</td>
</tr>
<tr>
<td align="left">Validation data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref026">26</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref027">27</xref>]</td>
<td align="left">8, 9, 17</td>
<td align="char" char=".">135</td>
<td align="left">6 over 3 days</td>
<td align="left">10.0 [5.3–13.3: 8.6–11.6]</td>
<td align="left">Venous plasma</td>
<td align="char" char=".">263</td>
<td align="left">2 [1–15: 1–2]</td>
<td align="left">127</td>
<td align="left">1 [1–1: 1–1]</td>
<td align="left">54.1/45.9</td>
<td align="left">3.0 [0.5–35.0: 1.9–4.0]</td>
<td align="left">11 [6–49: 10–14]</td>
<td align="left">−1.5 [−5.3 to 2.6: −2.3 to −0.9]</td>
<td align="left">36,600 [280–450,000: 11,600–101,000]</td>
<td align="char" char=".">1.5</td>
<td align="left">18 [13–22: 15–20]</td>
</tr>
<tr>
<td align="left" rowspan="4"><bold>PK/PD day 42 efficacy data</bold></td>
<td align="left">All data</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref006">6</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref009">9</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref014">14</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref022">22</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref025">25</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref043">43</xref>]</td>
<td align="left">1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22</td>
<td align="char" char=".">3,486</td>
<td align="left">6 over 3 days, 6 over 5 days, 4 over 3 days, 3 over 3 days</td>
<td align="left">10.8 [3.2–24.0: 9.2–12.6]</td>
<td align="left">Venous plasma, capillary plasma, venous blood, capillary blood</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">52.6/47.4</td>
<td align="left">6.6 [0.0–86.7: 3.1–19.0]</td>
<td align="left">19 [5–150: 12–46]</td>
<td align="left">−1.0 [−5.3 to 10.5: −1.8 to −0.3]</td>
<td align="left">16,400 [13–629,000: 2,730–50,300]</td>
<td align="char" char=".">4.7</td>
<td align="left">22 [13–39: 19–28]</td>
</tr>
<tr>
<td align="left">African children &lt;15 kg</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref026">26</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref028">28</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref036">36</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref037">37</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref039">39</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref043">43</xref>]</td>
<td align="left">1, 2, 3, 5, 6, 7, 8, 11, 12, 13, 14, 16, 18, 21, 22</td>
<td align="char" char=".">1,210</td>
<td align="left">6 over 3 days</td>
<td align="left">10.7 [8.1–24.0: 9.2–12.0]</td>
<td align="left">Venous plasma, venous blood, capillary blood</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">50.3/49.7</td>
<td align="left">2.5 [0.0–14.5: 1.7–3.4]</td>
<td align="left">11 [5–15: 10–13]</td>
<td align="left">−1.1 [−5.3 to 10.5: −1.9 to −0.5]</td>
<td align="left">35,500 [120–629,000: 11,400–72,800]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">African children 15–25 kg</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref025">25</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref026">26</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref028">28</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref036">36</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref043">43</xref>]</td>
<td align="left">1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16, 18, 21, 22</td>
<td align="char" char=".">638</td>
<td align="left">6 over 3 days</td>
<td align="left">13.3 [9.8–18.9: 12.0–15.0]</td>
<td align="left">Venous plasma, venous blood, capillary blood</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">50/50</td>
<td align="left">5.7 [2.1–18.8: 4.4–7.5]</td>
<td align="left">18 [15–25: 16–20]</td>
<td align="left">−0.7 [−4.1 to 2.3: −1.4 to 0.0]</td>
<td align="left">17,600 [32–4 × 10<sup>5</sup>: 3,530–48,300]</td>
<td align="char" char=".">0</td>
<td align="left">—</td>
</tr>
<tr>
<td align="left">Southeast Asian pregnant women</td>
<td align="left">[<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref006">6</xref>]</td>
<td align="left">17</td>
<td align="char" char=".">113</td>
<td align="left">6 over 3 days</td>
<td align="left">9.8 [7.4–13.7: 9.1–10.4]</td>
<td align="left">Venous plasma, capillary plasma</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">—</td>
<td align="left">0/100</td>
<td align="left">24.0 [14.0–42.0: 20.0–33.0]</td>
<td align="left">49 [35–65: 46–53]</td>
<td align="left">—</td>
<td align="left">3,190 [57–154,000: 624–20,100]</td>
<td align="char" char=".">100</td>
<td align="left">23 [13–39: 18–291]</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Data are presented as median [range: interquartile range].</p></fn>
<fn id="t001fn002"><p>Included study sites were Benin (1); Bandim Health Projects study area (Bandim, Belem, and Cuntum), Guinea-Bissau (2); Fukayosi, Tanzania (3); Kampala, Uganda (4); Kenya (5); Kibaha District, Tanzania (6); Kilifi, Kenya (7); Kilombero District, Tanzania (8); Madang and East Sepik Provinces, Papua New Guinea (9); Madang Province, Papua New Guinea (10); Mali (11); Mbarara, Uganda (12); Mozambique, Mozambique (13); Nimba County, Liberia (14); Phalanxay District, Laos (15); Sekou, Liberia (16); Shoklo Malaria Research Unit, Thailand (17); Allada, Benin (18); Bangkok, Thailand (19); Battambang Province, Cambodia (20); Tanzania (21); and Yombo, Tanzania (22).</p></fn>
<fn id="t001fn003"><p>DLF, desbutyl-lumefantrine; LF, lumefantrine; LLOQ, lower limit of quantification; PD, pharmacodynamic; PK, pharmacokinetic.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The following covariates were selected prospectively and their influence evaluated using a population modelling approach: body weight, pregnancy, estimated gestational age, baseline parasitaemia, dosage (mg/kg), dose per occasion (mg), total daily dose (mg), total dose (mg), and age-for-weight <italic>z-</italic>score. Some clinically relevant covariates were not available for all patients; these included haemoglobin (available for 2,901 patients; either directly measured or calculated from measured haematocrit [<xref ref-type="bibr" rid="pmed.1002579.ref044">44</xref>]) and baseline body temperature (axillary available for 3,029 patients, tympanic available for 427 patients, and oral available for 100 patients). Pooling of temperature data (i.e., axillary, oral, and tympanic) was considered unreliable due to potential discrepancies between study-site procedures and was therefore not performed. A separated covariate analysis was performed on a subset of data in order to evaluate baseline body temperature and haemoglobin as covariates.</p>
<sec id="sec013">
<title>Lumefantrine pharmacokinetic model</title>
<sec id="sec014">
<title>Structural model</title>
<p>The lumefantrine pharmacokinetic model was developed based on data from 1,347 patients. This subset contained relatively densely sampled venous plasma data (i.e., 2 or more samples per patient) and covered a wide range of covariates (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>). Disposition pharmacokinetics was best described using a 2-compartment model, as this model was superior to a 1-compartment model (<italic>p</italic> &lt; 0.001; Δ−2LL = −2,361; ΔAIC = −2,357). The addition of a third compartment did not result in further significant improvement (<italic>p</italic> &gt; 0.01; Δ−2LL = −6.97, ΔAIC = −2.97). A first-order absorption model described the lumefantrine absorption characteristics adequately, and residual variability was described using an additive error model on logarithmic data (<xref ref-type="fig" rid="pmed.1002579.g002">Fig 2</xref>).</p>
<fig id="pmed.1002579.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Prediction-corrected visual predictive checks.</title>
<p>(A) Prediction-corrected visual predictive check of the lumefantrine population pharmacokinetic model, with the insert representing the first 15 hours after dose. (B and C) Prediction-corrected visual predictive check of the lumefantrine/desbutyl-lumefantrine drug-metabolite model stratified for lumefantrine (B) and desbutyl-lumefantrine (C). The inserts in (B) and (C) show the predictive performance during the first 110 hours after dose. Open circles represent observed plasma concentration data. The solid lines represent the 5th, 50th, and 95th percentiles of the observed data. The grey shaded areas represent the 95% confidence intervals of the simulated (<italic>n =</italic> 2,000) percentiles.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Disease- and dosage-related covariate model</title>
<p>Day 7 lumefantrine concentrations decreased with increasing pre-treatment parasitaemias described using a power relationship between bioavailability and pre-treatment parasite count (<inline-formula id="pmed.1002579.e001"><alternatives><graphic id="pmed.1002579.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e001" xlink:type="simple"/><mml:math display="inline" id="M1"><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">θ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mo>−</mml:mo><mml:mn>4.2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>; coefficient −0.643; <italic>p &lt;</italic> 0.001; Δ−2LL = −49.4; ΔAIC = −47.4; <xref ref-type="table" rid="pmed.1002579.t002">Table 2</xref>). Moreover, lumefantrine displayed dose-limited absorption, which was parameterised in the model using a maturation effect (50% saturation of the absorption [dose<sub>50</sub>] at 3.42 mg/kg; dose<sub>90</sub> at approximately 36 mg/kg) on relative bioavailability (<italic>p &lt;</italic> 0.001; Δ−2LL = −64.6; ΔAIC = −62.6; <xref ref-type="table" rid="pmed.1002579.t002">Table 2</xref>).</p>
<table-wrap id="pmed.1002579.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.t002</object-id>
<label>Table 2</label> <caption><title>Population parameter estimates from the final lumefantrine pharmacokinetic model.</title></caption>
<alternatives>
<graphic id="pmed.1002579.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Parameter</th>
<th align="left" colspan="2">Fixed effects</th>
<th align="left" colspan="2">Random effects</th>
</tr>
<tr>
<th align="left">Population estimate (BS estimate)</th>
<th align="left">%RSE (95% CI)</th>
<th align="left">%CV for IIV (BS estimate)</th>
<th align="left">%RSE (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>F</italic></td>
<td align="char" char=".">1 (fixed)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">70.3 (70.2)</td>
<td align="char" char=".">5.95 (65.3–75.3)</td>
</tr>
<tr>
<td align="left">Box–Cox shape parameter on <italic>F</italic></td>
<td align="char" char=".">−0.343 (−0.342)</td>
<td align="char" char=".">19.5 (−0.469 to 0.215)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>k</italic><sub>a</sub> (h<sup>−1</sup>)</td>
<td align="char" char=".">0.0386 (0.0388)</td>
<td align="char" char=".">2.72 (0.0368 to 0.0410)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">CL/<italic>F</italic> (l/h)</td>
<td align="char" char=".">1.35 (1.36)</td>
<td align="char" char=".">29.7 (0.538 to 2.19)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>C</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">11.2 (11.6)</td>
<td align="char" char=".">30.3 (4.65 to 18.8)</td>
<td align="char" char=".">144 (141)</td>
<td align="char" char=".">10.8 (115–165)</td>
</tr>
<tr>
<td align="left"><italic>Q/F</italic> (l/h)</td>
<td align="char" char=".">0.344 (0.350)</td>
<td align="char" char=".">29.8 (0.137 to 0.566)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>P</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">59.0 (59.5)</td>
<td align="char" char=".">29.7 (23.6 to 96.4)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">Dose<sub>50</sub> (mg/kg) on <italic>F</italic></td>
<td align="char" char=".">3.86 (4.07)</td>
<td align="char" char=".">41.5 (1.25 to 8.04)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">Pregnancy on <italic>k</italic><sub>a</sub></td>
<td align="char" char=".">0.352 (0.355)</td>
<td align="char" char=".">21.2 (0.212 to 0.510)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">Parasitaemia on <italic>F</italic></td>
<td align="char" char=".">−0.643 (−0.635)</td>
<td align="char" char=".">13.0 (−0.793 to 0.473)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">σ</td>
<td align="char" char=".">0.323 (0.323)</td>
<td align="char" char=".">4.88 (0.293 to 0.357)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Coefficient of variation (%CV) for inter-individual variability (IIV) was calculated as <inline-formula id="pmed.1002579.e002"><alternatives><graphic id="pmed.1002579.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e002" xlink:type="simple"/><mml:math display="inline" id="M2"><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:msqrt></mml:math></alternatives></inline-formula>. The relative standard error (%RSE) was calculated as <inline-formula id="pmed.1002579.e003"><alternatives><graphic id="pmed.1002579.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e003" xlink:type="simple"/><mml:math display="inline" id="M3"><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula> from 1,000 iterations of a non-parametric bootstrap (BS) procedure. The 95% confidence interval (95% CI) is displayed as the 2.5th to 97.5th percentile of the BS estimate, and the BS estimate as the average value.</p></fn>
<fn id="t002fn002"><p><italic>F</italic>: relative bioavailability; Box–Cox shape parameter: shape parameter on Box–Cox transformation; <italic>k</italic><sub>a</sub>: absorption rate constant; CL/<italic>F</italic>: elimination clearance; <italic>V</italic><sub>C</sub>/<italic>F</italic>: apparent central volume of distribution; <italic>Q/F</italic>: inter-compartmental clearance; <italic>V</italic><sub>P</sub>/<italic>F</italic>: apparent peripheral volume of distribution; dose<sub>50</sub>: dose (mg/kg) needed for half of maximum dose-dependent saturation of <italic>F</italic>; pregnancy: categorical covariate effect of pregnancy on <italic>k</italic><sub>a</sub>; parasitaemia: continuous covariate effect of enrolment parasite density on <italic>F</italic>; and σ: additive residual error on log scale. All parameters were centred on a non-pregnant patient weighing 42 kg with an admission parasitaemia of 15,800 parasites/μl.</p></fn>
<fn id="t002fn003"><p>Clearance and volume parameters were centred on the median body weight (WT) and scaled allometrically (<inline-formula id="pmed.1002579.e004"><alternatives><graphic id="pmed.1002579.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e004" xlink:type="simple"/><mml:math display="inline" id="M4"><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>); dose-dependent absorption was implemented as a saturation model (<inline-formula id="pmed.1002579.e005"><alternatives><graphic id="pmed.1002579.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e005" xlink:type="simple"/><mml:math display="inline" id="M5"><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">θ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>); baseline parasitaemia was implemented as an exponential relationship centred on the median natural logarithm transformed value (<inline-formula id="pmed.1002579.e006"><alternatives><graphic id="pmed.1002579.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e006" xlink:type="simple"/><mml:math display="inline" id="M6"><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">θ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mo>−</mml:mo><mml:mn>4.2</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), and the categorical pregnancy effect was implemented as a proportional effect (<italic>k</italic><sub>a</sub> = θ(<italic>n</italic>) × (1 + θ<sub>pregnancy</sub>)).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec016">
<title>Children</title>
<p>The currently recommended 6-dose regimen in children weighing &lt;15 kg and 15–24 kg resulted in 24.2% and 13.4% lower predicted median venous lumefantrine concentrations at day 7, respectively, when compared to adult patients (<xref ref-type="fig" rid="pmed.1002579.g003">Fig 3</xref>). This resulted from body weight, implemented as a covariate on clearance (<inline-formula id="pmed.1002579.e007"><alternatives><graphic id="pmed.1002579.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e007" xlink:type="simple"/><mml:math display="inline" id="M7"><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>) and volume (<inline-formula id="pmed.1002579.e008"><alternatives><graphic id="pmed.1002579.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e008" xlink:type="simple"/><mml:math display="inline" id="M8"><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>) parameters (<italic>p &lt;</italic> 0.001; Δ−2LL = −271; ΔAIC = −271; <xref ref-type="table" rid="pmed.1002579.t002">Table 2</xref>).</p>
<fig id="pmed.1002579.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Body weight, pregnancy status, admission parasitaemia, and dosage effects on predicted day 7 venous plasma lumefantrine concentrations (<italic>n =</italic> 2,000).</title>
<p>Body weight (top left); pregnancy status (top right); admission parasitaemia (bottom left); dosage (bottom right). Boxes and whiskers represent 25%–75% and 2.5%–97.5% of the data, respectively. The grey solid, dashed, and dotted lines represent 596 ng/ml (median lumefantrine concentration at day 7 in non-pregnant adult patients after a standard treatment), 200 ng/ml [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>], and 175 ng/ml [<xref ref-type="bibr" rid="pmed.1002579.ref023">23</xref>], respectively. The dotted black line in the parasitaemia panel represents the mean of the simulated data (open grey circles).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.g003" xlink:type="simple"/>
</fig>
<p>Furthermore, weight-for-age <italic>z-</italic>scores [<xref ref-type="bibr" rid="pmed.1002579.ref045">45</xref>] were calculated and tested as a linear covariate for children below 5 years of age (<italic>n</italic> = 281) or below 3 years of age (<italic>n</italic> = 139). Weight-for-age <italic>z-</italic>scores did not correlate with pharmacokinetic parameters in any of the tested age ranges, and age as a proxy for hepatic enzyme maturation did not significantly improve the model fit when included as a covariate on elimination clearance.</p>
</sec>
<sec id="sec017">
<title>Pregnant women</title>
<p>Lumefantrine distribution kinetics was substantially affected in pregnant women during their second and third trimester when compared to non-pregnant adults (<italic>p &lt;</italic> 0.001; Δ−2LL = −21.8; ΔAIC = −19.8; <xref ref-type="table" rid="pmed.1002579.t002">Table 2</xref>), resulting in 20.2% lower day 7 venous lumefantrine concentrations (<italic>k</italic><sub>a</sub> = θ(<italic>n</italic>) × (1 + θ<sub>pregnancy</sub>)).</p>
</sec>
</sec>
<sec id="sec018">
<title>Baseline body temperature and haemoglobin</title>
<p>Haemoglobin and admission body temperature were not formally evaluated using a stepwise modelling approach in the population pharmacokinetic model as these covariates were missing for more than 20% of the patients. However, the covariates were evaluated in a separate sub-group covariate analysis, and baseline body temperature did not correlate with any lumefantrine pharmacokinetic parameter in the current population pharmacokinetic model. Measured or haematocrit-derived haemoglobin concentration was available for 74% of the patients and correlated significantly with lumefantrine inter-compartmental clearance (<italic>p &lt;</italic> 0.001; Δ−2LL = −19.3; ΔAIC = −17.3; exponential relationship with an exponent of 0.0629) and apparent peripheral distribution volume (<italic>p &lt;</italic> 0.001; Δ−2LL = −11.5; ΔAIC = −9.5; power relationship with a power of 1.44). This correlation resulted in increasing day 7 venous plasma lumefantrine concentrations with higher haemoglobin levels.</p>
<sec id="sec019">
<title>Model validation</title>
<p>The final model showed accurate and precise predictive power without indications of model misspecification, using internal data as well as external validation data from 401 patients with sparse venous plasma sampling (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>; Figs <xref ref-type="fig" rid="pmed.1002579.g002">2</xref>, <xref ref-type="supplementary-material" rid="pmed.1002579.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pmed.1002579.s003">S2</xref>). The bootstrap diagnostics (<italic>n</italic> = 1,000) confirmed robust parameter estimates with reasonable relative standard errors (<xref ref-type="table" rid="pmed.1002579.t002">Table 2</xref>). Eta-shrinkage on apparent volume of distribution of the central compartment and relative bioavailability was 47.5% and 15.2%, respectively.</p>
<p>More technical information regarding the lumefantrine pharmacokinetic model can be found in <xref ref-type="supplementary-material" rid="pmed.1002579.s010">S2 Text</xref>.</p>
</sec>
<sec id="sec020">
<title>Matrix and formulation effects</title>
<p>Prediction-corrected visual predictive checks for matrix- and formulation-related subsets of the data were generated from the lumefantrine model on venous plasma data using proportional adjustment and showed adequate predictive performance except for capillary plasma (<xref ref-type="supplementary-material" rid="pmed.1002579.s003">S2 Fig</xref>). Only venous blood data displayed a minor over-prediction of the 5th and 95th percentiles (<xref ref-type="supplementary-material" rid="pmed.1002579.s003">S2 Fig</xref>), although mean trends could still be predicted accurately, and estimated proportional differences in lumefantrine exposures would therefore be unbiased. Lumefantrine concentrations were on average 11.3%, 18.3%, and 23.8% lower in studies measuring venous blood (<italic>n =</italic> 595), capillary plasma (<italic>n =</italic> 191), and capillary blood (<italic>n =</italic> 840), respectively, when compared to the studies measuring lumefantrine in venous plasma after intact tablets (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>; <xref ref-type="supplementary-material" rid="pmed.1002579.s003">S2 Fig</xref>). Venous plasma lumefantrine concentrations in studies where patients received dispersible (<italic>n =</italic> 287) and crushed (<italic>n =</italic> 278) tablets were on average 6.31% and 26.0% higher, respectively, when compared to studies measuring lumefantrine in venous plasma after intact tablets (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>; <xref ref-type="supplementary-material" rid="pmed.1002579.s003">S2 Fig</xref>).</p>
</sec>
</sec>
<sec id="sec021">
<title>Pharmacokinetic-pharmacodynamic time-to-event model</title>
<p>For the pharmacokinetic-pharmacodynamic time-to-event model, individual pharmacokinetic parameter estimates from 3,486 patients were fixed and evaluated with the treatment outcome at day 42 (<xref ref-type="table" rid="pmed.1002579.t003">Table 3</xref>). Overall, 93 out of 3,486 patients (2.67%) had recrudescent infections. A Gompertz hazard model with a sigmoidal <italic>E</italic><sub>MAX</sub> lumefantrine drug effect model provided accurate predictive power in the visual predictive check (<xref ref-type="fig" rid="pmed.1002579.g004">Fig 4</xref>), but parameter estimates lacked precision and accuracy (<xref ref-type="table" rid="pmed.1002579.t003">Table 3</xref>). No statistically significant covariates were found for the pharmacodynamic parameters in the full dataset, which could be a consequence of biased distribution of covariates over the geographical regions and the small number of recrudescent infections.</p>
<fig id="pmed.1002579.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Visual predictive check of the pharmacokinetic-pharmacodynamic time-to-event model.</title>
<p>The grey shaded area represents the 95% confidence interval of the simulated (<italic>n =</italic> 2,000) data. Solid and dashed black lines represent the Kaplan–Meier estimator and corresponding standard errors. Panels show all data (top left), African children &lt;15 kg (top right), African children ≥15 kg and &lt;25 kg (bottom left), and pregnant women from Southeast Asia (bottom right).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pmed.1002579.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.t003</object-id>
<label>Table 3</label> <caption><title>Parameter estimates from the pharmacokinetic-pharmacodynamic time-to-event model.</title></caption>
<alternatives>
<graphic id="pmed.1002579.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="3">Parameter</th>
<th align="left" colspan="8">Day 42 study outcome</th>
</tr>
<tr>
<th align="left" colspan="2">All data</th>
<th align="left" colspan="2">African children &lt;15 kg</th>
<th align="left" colspan="2">African children 15–25 kg</th>
<th align="left" colspan="2">Southeast Asian pregnant women</th>
</tr>
<tr>
<th align="left">Population estimate<break/>(BS estimate)</th>
<th align="left">%RSE<break/>(95% CI)</th>
<th align="left">Population estimate<break/>(BS estimate)</th>
<th align="left">%RSE<break/>(95% CI)</th>
<th align="left">Population estimate<break/>(BS estimate)</th>
<th align="left">%RSE<break/>(95% CI)</th>
<th align="left">Population estimate<break/>(BS estimate)</th>
<th align="left">%RSE<break/>(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Baseline hazard (day<sup>−1</sup>)</td>
<td align="left">0.00600<break/>(0.0103)</td>
<td align="left">110<break/>(0.00231–0.0406)</td>
<td align="left">0.00120<break/>0.00120</td>
<td align="left">23.4<break/>(0.000775–0.00199)</td>
<td align="left">0.00168<break/>0.00264</td>
<td align="left">158<break/>(0.000370–0.00893)</td>
<td align="left">0.00324<break/>0.00329</td>
<td align="left">30.8<break/>(0.00149–0.00535)</td>
</tr>
<tr>
<td align="left">Hazard half-life (day)</td>
<td align="left">12.8<break/>(14.3)</td>
<td align="left">67.4<break/>(6.92–31.8)</td>
<td align="left" colspan="2">—</td>
<td align="left" colspan="2">—</td>
<td align="left" colspan="2">—</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> (ng/ml)</td>
<td align="left">92.6<break/>(94.7)</td>
<td align="left">56.0<break/>(10.3–202)</td>
<td align="left">194<break/>(465)</td>
<td align="left">457<break/>(35.2–2,410)</td>
<td align="left">9.79<break/>(18.5)</td>
<td align="left">162<break/>(0.703–87.1)</td>
<td align="left">1,580<break/>(863)</td>
<td align="left">38.4<break/>(307–1,600)</td>
</tr>
<tr>
<td align="left">Slope</td>
<td align="left">1.87<break/>(2.98)</td>
<td align="left">181<break/>(0.979–9.46)</td>
<td align="left" colspan="2">—</td>
<td align="left" colspan="2">—</td>
<td align="left" colspan="2">—</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>The relative standard error (%RSE) was calculated as <inline-formula id="pmed.1002579.e009"><alternatives><graphic id="pmed.1002579.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e009" xlink:type="simple"/><mml:math display="inline" id="M9"><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula> from 1,000 iterations of a non-parametric bootstrap (BS) procedure.</p></fn>
<fn id="t003fn002"><p>IC<sub>50</sub>, half maximal inhibitory concentration.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>To avoid these potential biases, 3 separate pharmacokinetic-pharmacodynamic time-to-event models were used to evaluate 1,210 African children weighing &lt;15 kg (<italic>n =</italic> 36; 2.98% recrudescence), 638 African children weighing 15–25 kg (<italic>n =</italic> 7; 1.10% recrudescence), and 113 Southeast Asian pregnant women (<italic>n =</italic> 11; 9.73% recrudescence) (<xref ref-type="fig" rid="pmed.1002579.g004">Fig 4</xref>; <xref ref-type="table" rid="pmed.1002579.t003">Table 3</xref>). Data from Southeast Asian pregnant women and African children were best described using a constant baseline hazard model with an <italic>E</italic><sub>MAX</sub> lumefantrine drug effect. All pharmacokinetic-pharmacodynamic time-to-event models in these particular populations displayed accurate predictive power (<xref ref-type="fig" rid="pmed.1002579.g004">Fig 4</xref>) in the visual predictive check, although parameter estimates lacked precision and accuracy (<xref ref-type="table" rid="pmed.1002579.t003">Table 3</xref>). Moreover, pregnancy was not a statistically significant covariate when data from pregnant and (matched) non-pregnant women in Southeast Asia only were analysed. Furthermore, no statistically significant covariates were found in the pharmacokinetic-pharmacodynamic time-to-event model in African children.</p>
</sec>
<sec id="sec022">
<title>In silico dose optimization</title>
<p>As lumefantrine exposures were lower in young children and pregnant women, 3 alternative dosing regimens were evaluated and compared. A dose increase for pregnant women in their second and third trimester (100 mg artemether and 600 mg lumefantrine twice daily for 3 days, i.e., 1 extra tablet per dose) and for children weighing between 5 kg and 25 kg (lumefantrine doses: 120 mg for children 5–6 kg, 180 mg for children 7–8 kg, 240 mg for children 9–13 kg, and 360 mg for children 14–23 kg, twice daily for 3 days) did not result in equivalent lumefantrine concentrations at day 7 compared to a non-pregnant adult population receiving the standard dose (<xref ref-type="supplementary-material" rid="pmed.1002579.s004">S3 Fig</xref>). However, the intensified dosing regimen (standard dose at 0, 8, 16, 24, 32, 40, 48, 56, and 64 hours) resulted in similar lumefantrine concentrations at day 7 compared to a non-pregnant adult population receiving the standard treatment (<xref ref-type="fig" rid="pmed.1002579.g005">Fig 5</xref>). An extended dosing regimen (standard dose twice daily for a total 5 days) displayed the highest probability of target attainment, with &gt;75% of the simulated lumefantrine concentrations at day 7 above the mean lumefantrine concentration at day 7 in a non-pregnant adult population receiving standard treatment (<xref ref-type="fig" rid="pmed.1002579.g005">Fig 5</xref>). Total exposure and maximum lumefantrine concentrations were similar after intensified (thrice daily) and extended (5 day) dosing regimens and were substantially higher than those with an increased dosing regimen (Figs <xref ref-type="fig" rid="pmed.1002579.g005">5</xref> and <xref ref-type="supplementary-material" rid="pmed.1002579.s004">S3</xref>).</p>
<fig id="pmed.1002579.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.g005</object-id>
<label>Fig 5</label>
<caption>
<title>In silico dose optimisations using Monte Carlo simulations (<italic>n =</italic> 2,000) with the final lumefantrine pharmacokinetic model for the different populations consisting of children weighing &lt;15 kg, 15–24 kg, and 25–34 kg; non-pregnant adults ≥35 kg; and pregnant women.</title>
<p>The left, middle, and right column represent the results after a standard, intensified, and extended dosing regimen, respectively. The boxes and whiskers represent 25%–75% and 2.5%–97.5% of the data, respectively. The horizontal dashed-dotted grey line in the upper panels represents the median lumefantrine concentration at day 7 after standard treatment in non-pregnant adult patients (801 ng/ml). The dashed and dotted grey horizontal lines in the upper panels represent previously defined lumefantrine day 7 target concentrations of 175 and 200 ng/ml [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref023">23</xref>]. The horizontal grey dashed lines in the middle and lower panels represent the median lumefantrine area under the curve (AUC) (647,025 h × ng/ml) and maximum concentration (<italic>C</italic><sub>MAX</sub>) (6,731 ng/ml) after standard treatment in a non-pregnant adult patient population.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec023">
<title>Lumefantrine/desbutyl-lumefantrine pharmacokinetic model</title>
<p>The lumefantrine/desbutyl-lumefantrine pharmacokinetic model was developed based on data from 159 patients contributing 2 or more venous plasma samples per patient with a wide range of covariates (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>). A 2-compartment distribution model provided a substantial improvement of the model fit (<italic>p &lt;</italic> 0.001; Δ−2LL = −281; ΔAIC = −277) compared to a 1-compartment distribution model, but the addition of a third disposition compartment did not improve the model further (<italic>p &gt;</italic> 0.01; Δ−2LL = −8.68; ΔAIC = −4.68) (<xref ref-type="table" rid="pmed.1002579.t004">Table 4</xref>). Apart from the effect of body weight on clearance and volume parameters, no further covariates were included in the model. Unfortunately, a robust evaluation of pregnancy was not possible due to the small sample size (<xref ref-type="table" rid="pmed.1002579.t001">Table 1</xref>). The basic goodness-of-fit plots and parameter estimates showed a robust model without indications of model misspecification (<xref ref-type="supplementary-material" rid="pmed.1002579.s005">S4 Fig</xref>). The predictive power was accurate considering the sampling design and sample size (Figs <xref ref-type="fig" rid="pmed.1002579.g002">2</xref> and <xref ref-type="supplementary-material" rid="pmed.1002579.s006">S5</xref>).</p>
<table-wrap id="pmed.1002579.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pmed.1002579.t004</object-id>
<label>Table 4</label> <caption><title>Population parameter estimates from the simultaneous pharmacokinetic lumefantrine/desbutyl-lumefantrine drug-metabolite model.</title></caption>
<alternatives>
<graphic id="pmed.1002579.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Parameter</th>
<th align="left" colspan="2">Fixed effects</th>
<th align="left" colspan="2">Random effects</th>
</tr>
<tr>
<th align="left">Population estimate (BS estimate)</th>
<th align="left">%RSE (95% CI parameter estimate)</th>
<th align="left">%CV for IIV (BS estimate)</th>
<th align="left">%RSE (95% CI parameter estimate)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>F</italic></td>
<td align="char" char=".">1 (fixed)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">57.9 (57.2)</td>
<td align="char" char=".">57.2 (49.0 to 64.9)</td>
</tr>
<tr>
<td align="left">Box–Cox shape parameter on <italic>F</italic></td>
<td align="char" char=".">−0.449 (−0.459)</td>
<td align="char" char=".">35.5 (−0.793 to −0.126)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>k</italic><sub>a</sub> (h<sup>−1</sup>)</td>
<td align="char" char=".">0.0409 (0.0422)</td>
<td align="char" char=".">13.3 (0.0349 to 0.0567)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">CL<sub>LF</sub>/<italic>F</italic> (l/h)</td>
<td align="char" char=".">1.56 (1.57)</td>
<td align="char" char=".">6.24 (1.40 to 1.77)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>C LF</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">21.2 (21.6)</td>
<td align="char" char=".">19.5 (14.6 to 30.5)</td>
<td align="char" char=".">111 (110)</td>
<td align="char" char=".">110 (87.5 to 134)</td>
</tr>
<tr>
<td align="left"><italic>Q</italic><sub>LF</sub>/<italic>F</italic> (l/h)</td>
<td align="char" char=".">0.381 (0.387)</td>
<td align="char" char=".">11.3 (0.313 to 0.497)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>P LF</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">53.8 (54.5)</td>
<td align="char" char=".">8.60 (46.2 to 65.2)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">CL<sub>DLF</sub>/<italic>F</italic> (l/h)</td>
<td align="char" char=".">78.4 (77.4)</td>
<td align="char" char=".">7.80 (64.6 to 88.5)</td>
<td align="char" char=".">38.8 (39.8)</td>
<td align="char" char=".">39.8 (32.0 to 51.0)</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>C DLF</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">2,470 (2,560)</td>
<td align="char" char=".">13.1 (1,960 to 3,280)</td>
<td align="char" char=".">86.0 (82.3)</td>
<td align="char" char=".">82.3 (49.5 to 110)</td>
</tr>
<tr>
<td align="left"><italic>Q</italic><sub>DLF</sub>/<italic>F</italic> (l/h)</td>
<td align="char" char=".">104 (103)</td>
<td align="char" char=".">13.2 (78.3 to 131)</td>
<td align="char" char=".">34.9 (33.8)</td>
<td align="char" char=".">33.8 (0.339 to 53.0)</td>
</tr>
<tr>
<td align="left"><italic>V</italic><sub>P DLF</sub>/<italic>F</italic> (l)</td>
<td align="char" char=".">8,650 (8,870)</td>
<td align="char" char=".">14.2 (6,990 to 11,800)</td>
<td align="char" char=".">47.7 (45.3)</td>
<td align="char" char=".">45.3 (0.453 to 68.9)</td>
</tr>
<tr>
<td align="left">Dose<sub>50</sub> (mg/kg) on <italic>F</italic></td>
<td align="char" char=".">3.86 (fixed)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">Pregnancy on <italic>k</italic><sub>a</sub></td>
<td align="char" char=".">0.513 (0.543)</td>
<td align="char" char=".">52.4 (0.264 to 0.889)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">Parasitaemia on <italic>F</italic></td>
<td align="char" char=".">−0.226 (−0.218)</td>
<td align="char" char=".">81.8 (−0.557 to 0.156)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">σ<sub>LF</sub></td>
<td align="char" char=".">0.251 (0.251)</td>
<td align="char" char=".">11.8 (0.196 to 0.315)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
<tr>
<td align="left">σ<sub>DLF</sub></td>
<td align="char" char=".">0.0560 (0.0559)</td>
<td align="char" char=".">8.46 (0.0467 to 0.0657)</td>
<td align="char" char=".">—</td>
<td align="char" char=".">—</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>Coefficient of variation (%CV) for inter-individual variability (IIV) was calculated as <inline-formula id="pmed.1002579.e010"><alternatives><graphic id="pmed.1002579.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e010" xlink:type="simple"/><mml:math display="inline" id="M10"><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:msqrt></mml:math></alternatives></inline-formula>. The relative standard error (%RSE) was calculated as <inline-formula id="pmed.1002579.e011"><alternatives><graphic id="pmed.1002579.e011g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e011" xlink:type="simple"/><mml:math display="inline" id="M11"><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula> from 1,000 iterations of a non-parametric bootstrap (BS) procedure. The 95% confidence interval (95% CI) is displayed as the 2.5th to 97.5th percentile of the BS estimate, and the BS estimate as the average value.</p></fn>
<fn id="t004fn002"><p>LF: lumefantrine; DLF: desbutyl-lumefantrine; <italic>F</italic>: relative bioavailability; Box–Cox shape parameter: shape parameter on Box–Cox transformation; <italic>k</italic><sub>a</sub>: absorption rate constant; <italic>V</italic><sub>C</sub>/<italic>F</italic>: apparent central volume of distribution; <italic>V</italic><sub>P</sub>/<italic>F</italic>: apparent peripheral volume of distribution; <italic>Q</italic>/<italic>F</italic>: inter-compartmental clearance; CL/<italic>F</italic>: elimination clearance; and σ: residual error additive on log scale. All parameters were centred around a non-pregnant patient with an admission parasitaemia of 15,800 parasites/μl, and clearance and volume parameters were centred around a non-pregnant patient weighing 42 kg and scaled allometrically (<inline-formula id="pmed.1002579.e012"><alternatives><graphic id="pmed.1002579.e012g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e012" xlink:type="simple"/><mml:math display="inline" id="M12"><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mo>/</mml:mo><mml:mi>Q</mml:mi><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>); parasitaemia was coded as in its logarithm in an exponential relationship centred around the mean (<inline-formula id="pmed.1002579.e013"><alternatives><graphic id="pmed.1002579.e013g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pmed.1002579.e013" xlink:type="simple"/><mml:math display="inline" id="M13"><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">θ</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">θ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mo>−</mml:mo><mml:mn>4.2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>), and a categorical pregnancy effect on <italic>k</italic><sub>a</sub> was coded as follows: <italic>k</italic><sub>a</sub> = θ × (1 + θ<sub>pregnant</sub>).</p></fn>
<fn id="t004fn003"><p>Pregnancy was a categorical/proportional covariate on <italic>F</italic> [1 + θ], dose<sub>50</sub> was implemented using a saturation model on <italic>F</italic> [1 − (Dose/(θ + Dose))], and admission parasitaemia was implemented using a power relationship on <italic>F</italic> [(parasitaemia/median value)<sup>θ</sup>].</p></fn>
</table-wrap-foot>
</table-wrap>
<p>More technical information regarding the lumefantrine/desbutyl-lumefantrine pharmacokinetic model can be found in <xref ref-type="supplementary-material" rid="pmed.1002579.s010">S2 Text</xref>.</p>
</sec>
</sec>
<sec id="sec024" sec-type="conclusions">
<title>Discussion</title>
<p>The population pharmacokinetic model based on this covariate-rich dataset from nearly 4,000 patients provides an improved understanding of how body weight, pregnancy, dosage, and admission parasitaemia affect the absorption, distribution, and elimination of the most important and widely used anti-malarial therapy in current use. By applying a pharmacokinetic-pharmacodynamic time-to-event model to this dataset, we have made, to the best of our knowledge, the first comprehensive attempt to evaluate the relationship between pharmacokinetic factors and AL treatment outcome (PCR-corrected recrudescent malaria infections) across different geographical areas and populations. The lumefantrine/desbutyl-lumefantrine population pharmacokinetic model provides an improved understanding of the disposition effect of lumefantrine’s main active metabolite, which had hitherto remained poorly characterised. Young children and pregnant women have lower lumefantrine exposures compared with non-pregnant adults. The reason that young children have relatively low lumefantrine exposure is that currently recommended AL dosage regimens do not adjust adequately for the non-linear relationship between body weight and systemic exposure. Pregnant women were underexposed due to changes in the distribution kinetics of lumefantrine. Underexposure in these vulnerable populations contributes to lower cure rates and the selection of parasite resistance. In silico dose optimisations utilising the lumefantrine population pharmacokinetic model provide a sound basis for proposing improved dosing regimens for these 2 vulnerable groups.</p>
<sec id="sec025">
<title>Lumefantrine pharmacokinetic model</title>
<p>Lumefantrine exposure and day 7 concentrations decreased substantially with increasing baseline parasite densities [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>]. Higher parasitaemias reflect more severe disease, which could reduce the absorption as a result of reductions in visceral blood flow. The dose dependency of lumefantrine absorption was consistent with a previous study from the Thailand–Myanmar border in which lumefantrine exposure in patients with uncomplicated malaria was 30% lower when once-daily doses were administered compared to when the same dose was divided between 2 daily doses [<xref ref-type="bibr" rid="pmed.1002579.ref014">14</xref>].</p>
<p>Weight-for-age <italic>z-</italic>score did not significantly improve the model fit when embedded in absorption, clearance, or distribution parameters. However, a pooled analysis on lumefantrine treatment outcome and day 7 concentration data showed a substantially higher risk of recrudescent malaria and lower concentrations at day 7 with decreasing weight-for-age <italic>z-</italic>scores [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref046">46</xref>]. Most probably the discrepancy between these 2 findings could be explained by the distribution of weight-for-age <italic>z-</italic>scores, which in this study had a large proportion of well-nourished (<italic>z-</italic>score between −2 and +2) children (214/281 children &lt;5 years and 108/139 children &lt;3 years). Moreover, weight-for-age <italic>z-</italic>score is an anthropometric indicator of both long-term (stunting) and short-term (wasting) nutritional status. The majority of the population studied here did not suffer from malnutrition, which could have affected significantly absorption, in contrast to the larger sample size studied previously. Weight-for-height <italic>z-</italic>scores may be a superior proxy for acute global malnutrition, especially in relation to drug pharmacology, but height was not available for all patients in the database.</p>
<p>Including age as a maturation factor for lumefantrine elimination clearance did not significantly improve the model fit. Maturation of enzymatic activity occurs during the first 2 years [<xref ref-type="bibr" rid="pmed.1002579.ref012">12</xref>], and the lack of data in the youngest children (in the model building dataset the youngest child was 6 months old and only 4 patients were below 1 year) might explain the absence of this covariate relationship.</p>
<p>An earlier meta-analysis of observed lumefantrine concentrations at day 7 that included 2,787 patients indicated substantially lower lumefantrine concentrations on day 7 in patients with documented fever (i.e., &gt;37.5°C admission axillary temperature) compared to patients without fever [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>]. Also, filter paper dried capillary blood lumefantrine concentrations at day 7 were lower with increasing haemoglobin levels in the same analysis [<xref ref-type="bibr" rid="pmed.1002579.ref016">16</xref>]. Admission body temperature and haemoglobin were evaluated here in a separate covariate analysis on a subset of data, but were not included in the final lumefantrine population pharmacokinetic model since these covariates were missing for more than 20% of the patients. In the patients in whom it was recorded, admission body temperature did not correlate significantly with any lumefantrine pharmacokinetic parameter in the current population pharmacokinetic model. The haemoglobin concentration did correlate with lumefantrine inter-compartmental clearance and apparent peripheral distribution volume, and, in contrast to previously published work, the results suggested somewhat higher lumefantrine concentrations at day 7 with increasing haemoglobin levels. However, the sampling matrix in this study was venous plasma as opposed to whole blood in filter paper, as in the previously reported study. Results should therefore be interpreted with caution.</p>
<p>Potential differences in lumefantrine distribution in venous blood and capillary blood when compared to venous plasma might not have been captured as venous and capillary blood samples were taken only at 7 days after treatment initiation. Thus, the reported proportional differences should be interpreted with caution. Increased lumefantrine exposures with crushed and dispersible tablets were in line with published results in healthy volunteers [<xref ref-type="bibr" rid="pmed.1002579.ref047">47</xref>]. However, similarly to the interpretation of matrix effects, proportional differences for formulation effects should be interpreted cautiously as the sparse sampling design (i.e., 1 sample per patient) prevented formal evaluation of bioequivalence. Matrix and formulation effects need further evaluation in prospective clinical studies before firm conclusions can be drawn.</p>
</sec>
<sec id="sec026">
<title>Lumefantrine pharmacokinetic-pharmacodynamic time-to-event model</title>
<p>No statistically significant clinical covariates could be found in the pharmacokinetic-pharmacodynamic time-to-event model. This indicated that treatment failures in vulnerable patient groups (e.g., children below 5 years of age and pregnant women) could be explained fully by reduced lumefantrine exposures.</p>
<p>However, the artemether/dihydroartemisinin drug effect was not included in the lumefantrine pharmacokinetic-pharmacodynamic time-to-event model nor was a desbutyl-lumefantrine effect [<xref ref-type="bibr" rid="pmed.1002579.ref048">48</xref>]. Consequently, all pharmacodynamic parameters, including baseline hazard and hazard half-life, are apparent, as the lumefantrine drug effect in the current pharmacokinetic-pharmacodynamic time-to-event model actually represents the sum of the artemether/dihydroartemisinin and lumefantrine/desbutyl-lumefantrine drug effects. Thus, the developed time-to-event model was not used for in silico dose optimisations because of the above issue in combination with poor parameter precision and accuracy of the pharmacokinetic-pharmacodynamic lumefantrine model.</p>
</sec>
<sec id="sec027">
<title>In silico dose optimisation</title>
<p>The high cure rates and excellent tolerability observed in non-pregnant adult patient populations suggest that conventional dosing in this group results in drug exposures within acceptably safe and effective therapeutic margins in most patients. Therefore, it is reasonable that dosage recommendations for other groups (including children and pregnant women) should be based on therapeutic targets that aim to achieve similar lumefantrine exposure (AUC and day 7 concentrations) to that of non-pregnant adults. This could improve cure rates in these groups and reduce the risks of drug resistance that could shorten AL’s useful therapeutic life [<xref ref-type="bibr" rid="pmed.1002579.ref002">2</xref>].</p>
<p>Administering higher individual doses at the currently recommended frequency and duration (i.e., by adding extra tablets to each dose in the usual twice-daily regimen) failed to result in proportional linear increases in overall drug exposures across all target populations. This presumably reflects dose-limited absorption. We modelled an additional 2 alternative dosing regimens: an intensified regimen (thrice-daily dosing with the currently recommended weight-based number of tablets per dose) and an extended regimen (with the currently recommended weight-based number of tablets per dose given twice daily for 5 days). Enrolment parasite density was not taken into account in dose optimisation simulations since quantification of parasites at enrolment is not always possible. Both alternative dosing regimens resulted in similar or higher lumefantrine concentrations on day 7 and AUCs than in non-pregnant adults given the currently recommended standard dosing regimen. However, higher maximum concentrations were not seen in these simulations, suggesting that pregnant women and young children receiving these regimens would not face added risks of peak drug exposure-related acute toxicity, although further investigation in prospective clinical studies would be required to confirm this [<xref ref-type="bibr" rid="pmed.1002579.ref006">6</xref>].</p>
<p>From a pharmacological perspective, a dose extension (i.e., twice-daily dosing at the current dosage for 5 days) for children ≤25 kg and pregnant women during the second and third trimester probably has the greatest advantages for therapeutic efficacy. A dose extension would result not only in adequate lumefantrine exposures but also, even more importantly, in an additional malaria asexual replication cycle being exposed to artemether/dihydroartemisinin. This would contribute to a lower parasite biomass. Unfortunately, artemether/dihydroartemisinin concentration-time data were not available in this study, which prevented us from formal clinical trial simulations using a pharmacokinetic-pharmacodynamic time-to-event approach for PCR-confirmed recrudescent malaria at day 42.</p>
<p>An extended dosing regimen needs to be considered in light of greater challenges in ensuring adherence to longer courses of anti-malarials. A 4-day treatment might be an option if a 5-day treatment is not possible due to poor adherence and/or cost issues. The alternative approach of intensifying frequency may also have programmatic disadvantages including dosing compliance with a more complex regimen and the need for repackaging, which increases the burden on pharmaceutical companies. The current development of a new formulation that provides increased lumefantrine absorption in animal and healthy volunteer studies might provide a solution [<xref ref-type="bibr" rid="pmed.1002579.ref049">49</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref050">50</xref>]. Nevertheless, until this formulation is commercially available, the efficacy, safety, and tolerability of the proposed regimens with the conventional formulation in children and pregnant women will require further evaluation in prospective clinical trials. Moreover, the population pharmacokinetic model developed in this study can be used for dose optimisation of the novel formulation as lumefantrine metabolism and elimination will remain the same.</p>
</sec>
<sec id="sec028">
<title>Study limitations</title>
<p>The developed lumefantrine population pharmacokinetic model and subsequent evaluation of alternative dosing regimens have a number of limitations. Model development was conducted using venous plasma data from patients receiving intact tablets administered with fat. Simulations, including evaluations and comparisons of alternative dosing regimens, are consequently representative only for venous plasma after administration of intact tablets with fat. Adjustments for sampling matrix (i.e., venous blood, capillary blood, or capillary plasma) or formulation (i.e., crushed or dispersible tablets) were not performed since correction factors were not considered reliable due to the sparseness of data. Furthermore, all patients included in this analysis received AL with fat, eliminating the possibility to characterise and quantify the impact of concomitant fat intake on the bioavailability of lumefantrine. The absence of artemether-dihydroartemisinin data prevented a full evaluation of AL therapy. Consequently, lumefantrine concentrations at day 7 were used as a pharmacokinetic endpoint. Nevertheless, the model remains clinically relevant considering that the vast majority of patients are treated with intact tablets co-administered with fat.</p>
<p>After the database was closed, 7 studies meeting the inclusion criteria were published (<xref ref-type="supplementary-material" rid="pmed.1002579.s008">S2 Table</xref>) [<xref ref-type="bibr" rid="pmed.1002579.ref010">10</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref012">12</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref013">13</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref051">51</xref>–<xref ref-type="bibr" rid="pmed.1002579.ref054">54</xref>]. Two studies in Malawi and Uganda evaluated lumefantrine pharmacokinetic drug–drug interactions with anti-retroviral therapies for HIV-co-infected paediatric patients [<xref ref-type="bibr" rid="pmed.1002579.ref052">52</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref054">54</xref>]. Drug–drug interaction data were not available in the pooled lumefantrine pharmacokinetic database, and therefore, these data would not have made a substantial impact on the analysis presented here. A total of 3 studies in pregnant women with uncomplicated <italic>P</italic>. <italic>falciparum</italic> malaria in Tanzania and Uganda were identified [<xref ref-type="bibr" rid="pmed.1002579.ref010">10</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref013">13</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref053">53</xref>]. All women studied were in their second and third trimester. Pregnant women in Tanzania and Uganda displayed a similar pattern of decreased lumefantrine exposure compared to non-pregnant women as in this pooled analysis [<xref ref-type="bibr" rid="pmed.1002579.ref010">10</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref053">53</xref>]. Unlike this pooled analysis, a study in Uganda did not report significant differences in lumefantrine exposure in pregnant and non-pregnant women, but a less powerful non-parametric, non-compartmental analysis was used, which could potentially explain this discrepancy [<xref ref-type="bibr" rid="pmed.1002579.ref013">13</xref>]. A study in Mali and Niger in severely malnourished children (weight-for-height <italic>z-</italic>score &lt; –3) between 6 months and 5 years found lower lumefantrine concentrations at day 7 compared to matched nourished children (weight-for-height <italic>z-</italic>score ≥ –3) [<xref ref-type="bibr" rid="pmed.1002579.ref051">51</xref>]. This pattern of lumefantrine underexposure with malnourishment was not apparent in this pooled study, a finding most likely explained by a discrepancy in <italic>z-</italic>score distributions, with a larger proportion of well-nourished (<italic>z-</italic>score between −2 and +2) children (214/281 children &lt;5 years and 108/139 children &lt;3 years) in the pooled analysis presented here. The impact of malnutrition on lumefantrine exposure needs to be evaluated further in a large pooled analysis including severely, moderately, and non-malnourished children from different regions. In line with the results presented here, a paediatric study in Uganda reported body weight as an allometric covariate for clearance and volume parameters, resulting in relatively lower lumefantrine exposure in small children [<xref ref-type="bibr" rid="pmed.1002579.ref012">12</xref>]. However, a positive correlation between lumefantrine exposure and age was also identified in the children in Uganda. In the pooled analysis presented here, baseline parasitaemia displayed a negative correlation with exposure. Thus, these correlated covariates (age and baseline parasitaemia correlate negatively) might be a likely explanation for the apparent discrepancy between the 2 studies.</p>
</sec>
<sec id="sec029">
<title>Conclusions</title>
<p>Conventional weight-based dosing in young children (≤25 kg) and pregnant women resulted in significantly lower lumefantrine drug exposures when compared to non-pregnant adults, and this may underpin poorer cure rates in these particularly vulnerable groups. Substantial dose-limited absorption of lumefantrine using the currently available formulation limits opportunities to improve drug exposure in these groups by just escalating the amount of drug administered with each dose. However, pharmacokinetic model-based simulations of alternative strategies suggest that, assuming similar adherence, intensified (3 times daily for 3 days) or extended (2 times daily for 5 days) dose regimens could result in equivalent lumefantrine exposures to those of non-pregnant adults treated conventionally. An extended dosing regimen is most favourable from a pharmacological perspective as an additional malaria asexual replication cycle is thereby exposed to artemether/dihydroartemisinin, which will undoubtedly contribute to increased parasitological killing. Given that AL is now the most widely used drug for treating the global burden of malaria illness, estimated at &gt;200 million cases annually, prospective clinical dose optimisation studies evaluating efficacy, safety, and tolerability, as well as both artemether/dihydroartemisinin and lumefantrine/desbutyl-lumefantrine pharmacokinetics, are now warranted in order to provide in vivo confirmation of our in silico findings for these proposed dosing regimens. Future research should also include evaluations of the regimens’ acceptability and adherence in order to determine the feasibility, practicality, and effectiveness of longer or more intense regimens. Implementing improved dosing regimens may have implications for reducing treatment failures in these vulnerable populations. Young African children represent the largest and most important population affected by malaria, and pregnant women are at higher risk of severe complications, death, and adverse pregnancy outcomes due to malaria. Improved dosing also has the potential benefit of limiting sub-therapeutic drug exposures at a population level, thereby reducing the risk of drug resistance and extending the therapeutic life of this important artemisinin-based combination treatment.</p>
</sec>
</sec>
<sec id="sec030">
<title>Supporting information</title>
<supplementary-material id="pmed.1002579.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s001" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<title/>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s002" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Goodness-of-fit diagnostics for lumefantrine when fitting the final lumefantrine pharmacokinetic model.</title>
<p>The black solid line, black dashed line, and open circles represent the line of identity, trend line, and observations, respectively.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s003" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>External validation and alternative sampling matrix prediction-corrected visual predictive checks.</title>
<p>External validation using prediction-corrected visual predictive check of sparse venous plasma sampling after intact tablets (A). Prediction-corrected visual predictive check of sparse venous plasma sampling data after dispersible tablets (B), sparse venous plasma sampling data after crushed tablets (C), sparse venous blood sampling data (D), sparse capillary blood sampling data (E), and dense capillary plasma sampling data (F). Open circles represent observed lumefantrine concentrations. Solid lines represent the 5th, 50th, and 95th percentiles of the observed data. Grey shaded areas represent the 95% confidence intervals of the 5th, 50th, and 95th percentiles of the simulated (<italic>n =</italic> 2,000) data.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s004" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s004" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>In silico dose optimisations using Monte Carlo simulations (<italic>n =</italic> 2,000) with the lumefantrine model.</title>
<p>The boxes and whiskers represent 25%–75% and 2.5%–97.5% of the data, respectively. The horizontal dashed-dotted grey line in the upper panel represents the median lumefantrine concentration at day 7 after standard treatment in a non-pregnant adult patient population (801 ng/ml). The dashed and dotted grey horizontal lines in the upper panel represent previously defined lumefantrine day 7 target concentrations of 175 and 200 ng/ml [<xref ref-type="bibr" rid="pmed.1002579.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002579.ref009">9</xref>]. The horizontal grey dashed lines in the middle and lower panels represent the median lumefantrine area under the curve (AUC) (647,025 h × ng/ml) and maximum concentration (<italic>C</italic><sub>MAX</sub>) (6,731 ng/ml) after standard treatment in a non-pregnant adult patient population.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s005" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s005" xlink:type="simple">
<label>S4 Fig</label>
<caption>
<title>Goodness-of-fit diagnostics for lumefantrine and desbutyl-lumefantrine when fitting the final pharmacokinetic drug-metabolite model.</title>
<p>Lumefantrine (top); desbutyl-lumefantrine (bottom). The black solid line, black dashed line, and open circles represent the line of identity, trend line, and observations, respectively.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s006" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s006" xlink:type="simple">
<label>S5 Fig</label>
<caption>
<title>External validation using prediction-corrected visual predictive check of the sparse venous plasma sampling.</title>
<p>Open circles represent the observed sparsely sampled desbutyl-lumefantrine venous plasma concentration data. Solid lines represent the 5th, 50th, and 95th percentiles of the observed data. Grey shaded areas represent the 95% confidence intervals of the 5th, 50th, and 95th percentiles of the simulated (<italic>n =</italic> 2,000) data.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s007" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s007" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Demographic summary of studies included in the pooled analyses.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s008" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s008" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Demographic summary of post-2013 studies meeting the original inclusion criteria.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s009" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s009" xlink:type="simple">
<label>S1 Text</label>
<caption>
<title>Supplementary methods: Detailed technical information regarding the pharmacokinetic model building process, the pharmacokinetic-pharmacodynamic time-to-event model building process, and dose optimisations.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pmed.1002579.s010" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmed.1002579.s010" xlink:type="simple">
<label>S2 Text</label>
<caption>
<title>Supplementary results: Detailed technical information on the pharmacokinetic model and dose optimisation results.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We sincerely thank the patients for their cooperation in completing the included studies. We also thank all lab staff, all nurses, and all administrative staff who have been involved in all these studies.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>ACT</term>
<def><p>artemisinin-based combination therapy</p></def>
</def-item>
<def-item><term>AL</term>
<def><p>artemether-lumefantrine</p></def>
</def-item>
<def-item><term>AUC</term>
<def><p>area under the curve</p></def>
</def-item>
<def-item><term>WWARN</term>
<def><p>WorldWide Antimalarial Resistance Network</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pmed.1002579.ref001"><label>1</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>. <chapter-title>World malaria report 2016</chapter-title>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2016</year>.</mixed-citation></ref>
<ref id="pmed.1002579.ref002"><label>2</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>. <chapter-title>Guidelines for the treatment of malaria</chapter-title>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2015</year>.</mixed-citation></ref>
<ref id="pmed.1002579.ref003"><label>3</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>. <chapter-title>World malaria report 2014</chapter-title>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref>
<ref id="pmed.1002579.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McGready</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Stepniewska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ashley</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>La</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Singhasivanon</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2006</year>;<volume>62</volume>(<issue>12</issue>):<fpage>1021</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00228-006-0199-7" xlink:type="simple">10.1007/s00228-006-0199-7</ext-link></comment> <object-id pub-id-type="pmid">17053895</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kloprogge</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Piola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dhorda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Muwanga</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Turyakira</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Apinan</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2013</year>;<volume>2</volume>:<fpage>e83</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/psp.2013.59" xlink:type="simple">10.1038/psp.2013.59</ext-link></comment> <object-id pub-id-type="pmid">24226803</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tarning</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>McGready</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ashley</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Pimanpanarak</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kamanikom</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated <italic>Plasmodium falciparum</italic> malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>(<issue>9</issue>):<fpage>3837</fpage>–<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00195-09" xlink:type="simple">10.1128/AAC.00195-09</ext-link></comment> <object-id pub-id-type="pmid">19564366</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tarning</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kloprogge</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Piola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dhorda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Muwanga</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Turyakira</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics of artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda</article-title>. <source>Malar J</source>. <year>2012</year>;<volume>11</volume>(<issue>1</issue>):<fpage>293</fpage>.</mixed-citation></ref>
<ref id="pmed.1002579.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tarning</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kloprogge</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Dhorda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jullien</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Nosten</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine and quinine in pregnant women with uncomplicated falciparum malaria in Uganda</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>(<issue>10</issue>):<fpage>5096</fpage>–<lpage>103</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00683-13" xlink:type="simple">10.1128/AAC.00683-13</ext-link></comment> <object-id pub-id-type="pmid">23917320</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salman</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Page-Sharp</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Griffin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kose</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Siba</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Ilett</surname> <given-names>KF</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>11</issue>):<fpage>5306</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.05136-11" xlink:type="simple">10.1128/AAC.05136-11</ext-link></comment> <object-id pub-id-type="pmid">21876056</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mosha</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Guidi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mwingira</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Abdulla</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mercier</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Decosterd</surname> <given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>8</issue>):<fpage>4583</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02595-14" xlink:type="simple">10.1128/AAC.02595-14</ext-link></comment> <object-id pub-id-type="pmid">24867986</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Checchi</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Piola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fogg</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bajunirwe</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Biraro</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Grandesso</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda</article-title>. <source>Malar J</source>. <year>2006</year>;<volume>5</volume>:<fpage>59</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-5-59" xlink:type="simple">10.1186/1475-2875-5-59</ext-link></comment> <object-id pub-id-type="pmid">16854236</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tchaparian</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sambol</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Arinaitwe</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>McCormack</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Bigira</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Wanzira</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria</article-title>. <source>J Infect Dis</source>. <year>2016</year>;<volume>214</volume>(<issue>8</issue>):<fpage>1243</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiw338" xlink:type="simple">10.1093/infdis/jiw338</ext-link></comment> <object-id pub-id-type="pmid">27471317</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nyunt</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Kajubi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ssebuliba</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kiconco</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Artemether-lumefantrine pharmacokinetics and clinical response are minimally altered in pregnant Ugandan women treated for uncomplicated falciparum malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>60</volume>(<issue>3</issue>):<fpage>1274</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01605-15" xlink:type="simple">10.1128/AAC.01605-15</ext-link></comment> <object-id pub-id-type="pmid">26666942</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashley</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Stepniewska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>McGready</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Annerberg</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hutagalung</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria</article-title>. <source>Trop Med Int Health</source>. <year>2007</year>;<volume>12</volume>(<issue>2</issue>):<fpage>201</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-3156.2006.01785.x" xlink:type="simple">10.1111/j.1365-3156.2006.01785.x</ext-link></comment> <object-id pub-id-type="pmid">17300626</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashley</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Stepniewska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Annerberg</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kham</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Brockman</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>How much fat is necessary to optimize lumefantrine oral bioavailability?</article-title> <source>Trop Med Int Health</source>. <year>2007</year>;<volume>12</volume>(<issue>2</issue>):<fpage>195</fpage>–<lpage>200</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-3156.2006.01784.x" xlink:type="simple">10.1111/j.1365-3156.2006.01784.x</ext-link></comment> <object-id pub-id-type="pmid">17300625</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group</collab>. <article-title>Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data</article-title>. <source>BMC Med</source>. <year>2015</year>;<volume>13</volume>:<fpage>227</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12916-015-0456-7" xlink:type="simple">10.1186/s12916-015-0456-7</ext-link></comment> <object-id pub-id-type="pmid">26381375</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref017"><label>17</label><mixed-citation publication-type="book" xlink:type="simple"><collab>WorldWide Antimalarial Resistance Network</collab>. <chapter-title>Data management and statistical analysis plan (DMSAP). Version 1.0</chapter-title>. <source>Pharmacology module</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>WorldWide Antimalarial Resistance Network</publisher-name>; <year>2011</year> [cited 2018 May 8]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.wwarn.org/sites/default/files/PharmacologyDMSAP.pdf" xlink:type="simple">http://www.wwarn.org/sites/default/files/PharmacologyDMSAP.pdf</ext-link>.</mixed-citation></ref>
<ref id="pmed.1002579.ref018"><label>18</label><mixed-citation publication-type="book" xlink:type="simple"><collab>WorldWide Antimalarial Resistance Network</collab>. <chapter-title>Clinical module: data management and statistical analysis plan. Version 1.2</chapter-title>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>WorldWide Antimalarial Resistance Network</publisher-name>; <year>2012</year> [cited 2018 May 9]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf" xlink:type="simple">http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf</ext-link>.</mixed-citation></ref>
<ref id="pmed.1002579.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>White</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Stepniewska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Barnes</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Price</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Simpson</surname> <given-names>J</given-names></name>. <article-title>Simplified antimalarial therapeutic monitoring: using the day-7 drug level?</article-title> <source>Trends Parasitol</source>. <year>2008</year>;<volume>24</volume>(<issue>4</issue>):<fpage>159</fpage>–<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pt.2008.01.006" xlink:type="simple">10.1016/j.pt.2008.01.006</ext-link></comment> <object-id pub-id-type="pmid">18353727</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>White</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>van Vugt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ezzet</surname> <given-names>F</given-names></name>. <article-title>Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine</article-title>. <source>Clin Pharmacokinet</source>. <year>1999</year>;<volume>37</volume>(<issue>2</issue>):<fpage>105</fpage>–<lpage>25</lpage>. <object-id pub-id-type="pmid">10496300</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Vugt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ezzet</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Phaipun</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Nosten</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>NJ</given-names></name>. <article-title>The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol)</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1998</year>;<volume>92</volume>(<issue>5</issue>):<fpage>564</fpage>–<lpage>5</lpage>. <object-id pub-id-type="pmid">9861382</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ezzet</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mull</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Karbwang</surname> <given-names>J</given-names></name>. <article-title>Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>1998</year>;<volume>46</volume>(<issue>6</issue>):<fpage>553</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1365-2125.1998.00830.x" xlink:type="simple">10.1046/j.1365-2125.1998.00830.x</ext-link></comment> <object-id pub-id-type="pmid">9862244</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Price</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Uhlemann</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>van Vugt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Brockman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hutagalung</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Nair</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>42</volume>(<issue>11</issue>):<fpage>1570</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/503423" xlink:type="simple">10.1086/503423</ext-link></comment> <object-id pub-id-type="pmid">16652314</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hietala</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>Martensson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ngasala</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Dahlstrom</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Annerberg</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>(<issue>11</issue>):<fpage>4780</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00252-10" xlink:type="simple">10.1128/AAC.00252-10</ext-link></comment> <object-id pub-id-type="pmid">20713675</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mwesigwa</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Parikh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>McGee</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>German</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Drysdale</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kalyango</surname> <given-names>JN</given-names></name>, <etal>et al</etal>. <article-title>Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00679-09" xlink:type="simple">10.1128/AAC.00679-09</ext-link></comment> <object-id pub-id-type="pmid">19841149</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hodel</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Kabanywanyi</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Malila</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zanolari</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Mercier</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Beck</surname> <given-names>HP</given-names></name>, <etal>et al</etal>. <article-title>Residual antimalarials in malaria patients from Tanzania—implications on drug efficacy assessment and spread of parasite resistance</article-title>. <source>PLoS ONE</source>. <year>2009</year>;<volume>4</volume>(<issue>12</issue>):<fpage>e8184</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0008184" xlink:type="simple">10.1371/journal.pone.0008184</ext-link></comment> <object-id pub-id-type="pmid">20011529</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karunajeewa</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Mueller</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Senn</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Law</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Gomorrai</surname> <given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>A trial of combination antimalarial therapies in children from Papua New Guinea</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>(<issue>24</issue>):<fpage>2545</fpage>–<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa0804915" xlink:type="simple">10.1056/NEJMoa0804915</ext-link></comment> <object-id pub-id-type="pmid">19064624</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Piola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fogg</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bajunirwe</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Biraro</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Grandesso</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ruzagira</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9469</issue>):<fpage>1467</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(05)66416-1" xlink:type="simple">10.1016/S0140-6736(05)66416-1</ext-link></comment> <object-id pub-id-type="pmid">15850630</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Piola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Nabasumba</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Turyakira</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Dhorda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nyehangane</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial</article-title>. <source>Lancet Infect Dis</source>. <year>2010</year>;<volume>10</volume>(<issue>11</issue>):<fpage>762</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(10)70202-4" xlink:type="simple">10.1016/S1473-3099(10)70202-4</ext-link></comment> <object-id pub-id-type="pmid">20932805</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vugt</surname> <given-names>MV</given-names></name>, <name name-style="western"><surname>Wilairatana</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gemperli</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Gathmann</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Phaipun</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Brockman</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria</article-title>. <source>Am J Trop Med Hyg</source>. <year>1999</year>;<volume>60</volume>(<issue>6</issue>):<fpage>936</fpage>–<lpage>42</lpage>. <object-id pub-id-type="pmid">10403324</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Vugt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Looareesuwan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wilairatana</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>McGready</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Villegas</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gathmann</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2000</year>;<volume>94</volume>(<issue>5</issue>):<fpage>545</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">11132386</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lefevre</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Looareesuwan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Treeprasertsuk</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Krudsood</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Silachamroon</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Gathmann</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand</article-title>. <source>Am J Trop Med Hyg</source>. <year>2001</year>;<volume>64</volume>(<issue>5–6</issue>):<fpage>247</fpage>–<lpage>56</lpage>. <object-id pub-id-type="pmid">11463111</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mayxay</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Khanthavong</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Keola</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Barends</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pongvongsa</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic</article-title>. <source>Clin Infect Dis</source>. <year>2004</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1139</fpage>–<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/424512" xlink:type="simple">10.1086/424512</ext-link></comment> <object-id pub-id-type="pmid">15486837</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Denis</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Tsuyuoka</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lindegardh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Yi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Top</surname> <given-names>SN</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia</article-title>. <source>Trop Med Int Health</source>. <year>2006</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1800</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-3156.2006.01739.x" xlink:type="simple">10.1111/j.1365-3156.2006.01739.x</ext-link></comment> <object-id pub-id-type="pmid">17176344</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Vugt</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Brockman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gemperli</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Luxemburger</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gathmann</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Royce</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1998</year>;<volume>42</volume>(<issue>1</issue>):<fpage>135</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">9449273</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Borrmann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sasi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mwai</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bashraheil</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Abdallah</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Muriithi</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e26005</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0026005" xlink:type="simple">10.1371/journal.pone.0026005</ext-link></comment> <object-id pub-id-type="pmid">22102856</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Djimde</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Tekete</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Abdulla</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lyimo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bassat</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Mandomando</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>9</issue>):<fpage>3994</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01115-10" xlink:type="simple">10.1128/AAC.01115-10</ext-link></comment> <object-id pub-id-type="pmid">21670177</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schramm</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Valeh</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Baudin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mazinda</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pinoges</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia</article-title>. <source>Malar J</source>. <year>2013</year>;<volume>12</volume>:<fpage>250</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-12-250" xlink:type="simple">10.1186/1475-2875-12-250</ext-link></comment> <object-id pub-id-type="pmid">23866736</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schramm</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Valeh</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Baudin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mazinda</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pinoges</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial</article-title>. <source>Malar J</source>. <year>2013</year>;<volume>12</volume>:<fpage>251</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-12-251" xlink:type="simple">10.1186/1475-2875-12-251</ext-link></comment> <object-id pub-id-type="pmid">23866774</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ursing</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kofoed</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Rodrigues</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Blessborn</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Thoft-Nielsen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bjorkman</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>203</volume>(<issue>1</issue>):<fpage>109</fpage>–<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiq001" xlink:type="simple">10.1093/infdis/jiq001</ext-link></comment> <object-id pub-id-type="pmid">21148503</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ngasala</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Malmberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Carlsson</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Ferreira</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Petzold</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Blessborn</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children &lt;5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>(<issue>7</issue>):<fpage>873</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/cir066" xlink:type="simple">10.1093/cid/cir066</ext-link></comment> <object-id pub-id-type="pmid">21427394</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ngasala</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Malmberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Carlsson</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Ferreira</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Petzold</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Blessborn</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study</article-title>. <source>Malar J</source>. <year>2011</year>;<volume>10</volume>:<fpage>64</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-10-64" xlink:type="simple">10.1186/1475-2875-10-64</ext-link></comment> <object-id pub-id-type="pmid">21410954</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faucher</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Aubouy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Adeothy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cottrell</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Doritchamou</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gourmel</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial</article-title>. <source>J Infect Dis</source>. <year>2009</year>;<volume>200</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/599378" xlink:type="simple">10.1086/599378</ext-link></comment> <object-id pub-id-type="pmid">19469703</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Stepniewska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Anstey</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ashley</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Barnes</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Binh</surname> <given-names>TQ</given-names></name>, <etal>et al</etal>. <article-title>The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria</article-title>. <source>Malar J</source>. <year>2008</year>;<volume>7</volume>:<fpage>149</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-7-149" xlink:type="simple">10.1186/1475-2875-7-149</ext-link></comment> <object-id pub-id-type="pmid">18673575</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref045"><label>45</label><mixed-citation publication-type="book" xlink:type="simple"><chapter-title>WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development.</chapter-title> <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2006</year>.</mixed-citation></ref>
<ref id="pmed.1002579.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group</collab>. <article-title>The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data</article-title>. <source>Lancet Infect Dis</source>. <year>2015</year>;<volume>15</volume>(<issue>6</issue>):<fpage>692</fpage>–<lpage>702</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(15)70024-1" xlink:type="simple">10.1016/S1473-3099(15)70024-1</ext-link></comment> <object-id pub-id-type="pmid">25788162</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdulla</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Amuri</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kabanywanyi</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Ubben</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Reynolds</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pascoe</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects</article-title>. <source>Malar J</source>. <year>2010</year>;<volume>9</volume>:<fpage>253</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-9-253" xlink:type="simple">10.1186/1475-2875-9-253</ext-link></comment> <object-id pub-id-type="pmid">20815879</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kloprogge</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>McGready</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hanpithakpong</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Blessborn</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Day</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated Plasmodium falciparum malaria on the Thailand-Myanmar border</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>10</issue>):<fpage>6375</fpage>–<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00267-15" xlink:type="simple">10.1128/AAC.00267-15</ext-link></comment> <object-id pub-id-type="pmid">26239986</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhandari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bhandari</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Sood</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jaswal</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rana</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bedi</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Improved pharmacokinetic and pharmacodynamic attributes of artemether-lumefantrine-loaded solid SMEDDS for oral administration</article-title>. <source>J Pharm Pharmacol</source>. <volume>201769</volume>(<issue>11</issue>):<fpage>1437</fpage>–<lpage>46</lpage>.</mixed-citation></ref>
<ref id="pmed.1002579.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jain</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Leong</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kalluri</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Koradia</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stein</surname> <given-names>DS</given-names></name>, <etal>et al</etal>. <article-title>Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<volume>61</volume>(<issue>9</issue>):<fpage>e00868</fpage>–<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00868-17" xlink:type="simple">10.1128/AAC.00868-17</ext-link></comment> <object-id pub-id-type="pmid">28630183</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Denoeud-Ndam</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dicko</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Baudin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Guindo</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Grandesso</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Diawara</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger</article-title>. <source>BMC Med</source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>):<fpage>167</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12916-016-0716-1" xlink:type="simple">10.1186/s12916-016-0716-1</ext-link></comment> <object-id pub-id-type="pmid">27776521</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Carey</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Lindsey</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Marzan</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gingrich</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Graham</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children</article-title>. <source>PLoS ONE</source>. <year>2017</year>;<volume>12</volume>(<issue>10</issue>):<fpage>e0186589</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0186589" xlink:type="simple">10.1371/journal.pone.0186589</ext-link></comment> <object-id pub-id-type="pmid">29065172</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mutagonda</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Kamuhabwa</surname> <given-names>AAR</given-names></name>, <name name-style="western"><surname>Minzi</surname> <given-names>OMS</given-names></name>, <name name-style="western"><surname>Massawe</surname> <given-names>SN</given-names></name>, <name name-style="western"><surname>Asghar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Homann</surname> <given-names>MV</given-names></name>, <etal>et al</etal>. <article-title>Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women</article-title>. <source>Malar J</source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>267</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12936-017-1914-9" xlink:type="simple">10.1186/s12936-017-1914-9</ext-link></comment> <object-id pub-id-type="pmid">28673292</object-id></mixed-citation></ref>
<ref id="pmed.1002579.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parikh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kajubi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ssebuliba</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kiconco</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Antiretroviral choice for HIV impacts antimalarial exposure and treatment outcomes in Ugandan children</article-title>. <source>Clin Infect Dis</source>. <year>2016</year>;<volume>63</volume>(<issue>3</issue>):<fpage>414</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciw291" xlink:type="simple">10.1093/cid/ciw291</ext-link></comment> <object-id pub-id-type="pmid">27143666</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>